Mouse Models of Atherosclerosis, Vascular Endothelial Growth Factors and Gene Therapy (Sydän- ja verisuonitautien hiirimallit ja VEGF ja geeniterapia) by Leppänen, Pia
Mouse Models of Atherosclerosis, 
Vascular Endothelial Growth
Factors and Gene Therapy
 
 
 
 
 
Doctoral dissertation
To be presented by permission of the Faculty of Natural and Enviromental Sciences
of the University of Kuopio for public examination in
Auditorium, Tietoteknia building, University of Kuopio,
on Friday 30th November 2007, at 1 p.m. 
Department of Biotechnology and Molecular Medicine
A.I . Virtanen Institute for Molecular Sciences
University of Kuopio
PIA LEPPÄNEN
JOKA
KUOPIO 2007
KUOPION YLIOPISTON JULKAISUJA G. - A.I. VIRTANEN -INSTITUUTTI 58
KUOPIO UNIVERSITY PUBLICATIONS G.
A.I. VIRTANEN INSTITUTE FOR MOLECULAR SCIENCES 58
Mouse Models of Atherosclerosis, 
Vascular Endothelial Growth
Factors and Gene Therapy
 
 
 
 
 
Doctoral dissertation
To be presented by permission of the Faculty of Natural and Enviromental Sciences
of the University of Kuopio for public examination in
Auditorium, Tietoteknia building, University of Kuopio,
on Friday 30th November 2007, at 1 p.m. 
Department of Biotechnology and Molecular Medicine
A.I . Virtanen Institute for Molecular Sciences
University of Kuopio
PIA LEPPÄNEN
JOKA
KUOPIO 2007
KUOPION YLIOPISTON JULKAISUJA G. - A.I. VIRTANEN -INSTITUUTTI 58
KUOPIO UNIVERSITY PUBLICATIONS G.
A.I. VIRTANEN INSTITUTE FOR MOLECULAR SCIENCES 58
Distributor :   Kuopio University Library
   P.O. Box 1627
   FI-70211 KUOPIO
   FINLAND
   Tel. +358 17 163 430
   Fax +358 17 163 410
   http://www.uku.fi/kirjasto/julkaisutoiminta/julkmyyn.html
Series Editors:   Research Director Olli Gröhn, Ph.D.
  Department of Neurobiology
  A.I . Virtanen Institute for Molecular Sciences
  Research Director Michael Courtney, Ph.D.
  Department of Neurobiology
  A.I . Virtanen Institute for Molecular Sciences
Author’s address:  Department of Biotechnology and Molecular Medicine
   A.I . Virtanen Institute for Molecular Sciences
   University of Kuopio
   P.O. Box 1627
   FI-70211 KUOPIO
   FINLAND
   E-mail : Pia.Leppanen@uku.fi 
Supervisors:   Professor Seppo Ylä-Herttuala, M.D., Ph.D.         
   Department of Biotechnology and Molecular Medicine
   A.I . Virtanen Institute for Molecular Sciences
   Professor Kari Airenne, Ph.D.
   Department of Biotechnology and Molecular Medicine
   A.I . Virtanen Institute for Molecular Sciences
   Docent Jukka Luoma, M.D., Ph.D.
   Department of Biotechnology and Molecular Medicine
   A.I . Virtanen Institute for Molecular Sciences
Reviewers:   Professor Jorge D. Erusalimsky, M.D., Ph.D.     
   Cardiff School of Health Sciences
   University of Wales Institute, UK     
   Docent Ken Lindstedt, Ph.D.
   Wihuri Research Institute
   Helsinki, Finland
Opponent:   Dosent Matti Jauhiainen, M.D., Ph.D.  
   Department of Molecular Medicine,
   National Public Health Institute, Biomedicum
   Helsinki, Finland
ISBN 978-951-27-0617-4
ISBN 978-951-27-0439-2 (PDF)
ISSN 1458-7335
Kopijyvä
Kuopio 2007
Finland
Distributor :   Kuopio University Library
   P.O. Box 1627
   FI-70211 KUOPIO
   FINLAND
   Tel. +358 17 163 430
   Fax +358 17 163 410
   http://www.uku.fi/kirjasto/julkaisutoiminta/julkmyyn.html
Series Editors:   Research Director Olli Gröhn, Ph.D.
  Department of Neurobiology
  A.I . Virtanen Institute for Molecular Sciences
  Research Director Michael Courtney, Ph.D.
  Department of Neurobiology
  A.I . Virtanen Institute for Molecular Sciences
Author’s address:  Department of Biotechnology and Molecular Medicine
   A.I . Virtanen Institute for Molecular Sciences
   University of Kuopio
   P.O. Box 1627
   FI-70211 KUOPIO
   FINLAND
   E-mail : Pia.Leppanen@uku.fi 
Supervisors:   Professor Seppo Ylä-Herttuala, M.D., Ph.D.         
   Department of Biotechnology and Molecular Medicine
   A.I . Virtanen Institute for Molecular Sciences
   Professor Kari Airenne, Ph.D.
   Department of Biotechnology and Molecular Medicine
   A.I . Virtanen Institute for Molecular Sciences
   Docent Jukka Luoma, M.D., Ph.D.
   Department of Biotechnology and Molecular Medicine
   A.I . Virtanen Institute for Molecular Sciences
Reviewers:   Professor Jorge D. Erusalimsky, M.D., Ph.D.     
   Cardiff School of Health Sciences
   University of Wales Institute, UK     
   Docent Ken Lindstedt, Ph.D.
   Wihuri Research Institute
   Helsinki, Finland
Opponent:   Dosent Matti Jauhiainen, M.D., Ph.D.  
   Department of Molecular Medicine,
   National Public Health Institute, Biomedicum
   Helsinki, Finland
ISBN 978-951-27-0617-4
ISBN 978-951-27-0439-2 (PDF)
ISSN 1458-7335
Kopijyvä
Kuopio 2007
Finland
Leppänen, Pia. Mouse Models of Atherosclerosis, Vascular Endothelial Growth Factors and Gene
Therapy. Kuopio University Publications G. - A.I. Virtanen Institute for Molecular Sciences 58.
2007. 91 p.
ISBN 978-951-27-0617-4
ISBN 978-951-27-0439-2 (PDF)
ISSN 1458-7335
ABSTRACT
In this thesis, I have studied different mouse models of atherosclerosis and some
safety issues concerning gene therapy in general and especially with regard to
vascular endothelial growth factors.
The studies described in this thesis showed that apoE3-Leiden-tg and LDLR/apoB48-
ko mouse models share similarities in the pathogenesis of atherosclerosis with the
human disease, and in view of the ability of macrophages to synthesize endogenous
apoE, they are good models for genetic and pathophysiological studies of
cardiovascular diseases. In safety studies, in situ PCR was found to be a sensitive
method to localize integrated viral vector DNA in different tissues, as it allowed the
comparison of transgene expression and possible morphological changes even if the
expression of the transgene had vanished.  In addition, we found that transient
expression of the members of the VEGF family does not enhance atherogenesis in
LDLR/apoB48-ko mice. In contrast, even a low long-term expression of VEGF can
cause significant pathological changes in target tissues.  Regarding vascular gene
therapy, short transient expression of the VEGF family members seems to be safe,
but tight regulation of the transgene expression seems to be a prerequisite for all
therapeutic applications aiming at long-term expression of VEGFs.
National Library of Medicine Classification: WG 550, QU 107, QU 450, QW 165.5.A3
Medical Subject Headings: atherosclerosis; cardiovascular diseases; mouse; vascular endothelial
growth factors; gene therapy; Adenoviridae/genetics
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1.  INTRODUCTION
Atherosclerosis is a common cause of mortality in the western countries and the
clinical complications of atherosclerosis are mainly due to occlusion of the vessels.
Vascular gene therapy offers a new promising treatment for cardiovascular diseases
and may become widely used in clinical applications. However, as the development
of atherosclerosis takes many years and involves different genes and environmental
factors, gene therapy is not yet a realistic option. Still, we have done some basic
animal studies of gene therapy for severe genetic defects like familiar
hypercholesterolemia and potential candidate genes with possible lipid lowering
effects (Pakkanen et al., 1999; Kankkonen et al., 2004/a; Jalkanen et al., 2003 a/b).
The current targets in vascular gene therapy nowadays are to achieve therapeutic
angiogenesis in peripheral and myocardial ischemia and prevention of the
postangioplasty and in-stent restenosis. Vascular endothelial growth factors (VEGFs)
are one of the gene families shown to enhance angiogenesis  and prevent restenosis in
ischemic tissues in experimental and clinical studies (Ylä-Herttuala and Martin,
2004). Still, ischemic gene therapy of VEGFs has not yet lead to permanent recovery
of the blood flow, because the functional collateral vessels fail to persist after
withdrawal of the growth factor. In addition, the biological effects of VEGFs
(especially VEGF-A) are remarkably dose-dependent and over-expression can result
in unwanted side effects (Lee at al., 2000; Garmeliet, 2000). One of the most
important difficulties in vascular gene therapy is the low transfection efficiency.
Furthermore, the development of large-scale production and purification methods for
the generation of high-titer clinical-grade viruses as needed in larger animal and
human trials seems to be problematic. Still, many developments in nonviral and viral
vectors have been under investigation as seen in recent reviews; Adv.Genet. 2005,
issue 53 (nonviral), Gene Ther. 2005 (Oct), issue 12 and Curr Gene Ther. 2005 (Aug)
issue 15 (viral). Before clinical trials, therapeutic genes and delivery as well as the
best vector have to be tested on cell cultures and, more importantly, on animal
13
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models. For many years, the mouse was not expected to be a model of atherosclerosis,
since it does not develop atherosclerosis in normal conditions. In addition, pathology
of the lesions developed using early high-fat diet formulations was different from
human atherosclerosis. New techniques to create transgenic and knockout mice have
changed the situation dramatically. Moreover, the development of microsurgery and
imaging technology has made the mouse a most attractive model of atherosclerosis
and in vivo gene therapy. Still, before clinical trials, the efficiency of the therapy and
the exact delivery routes need to be tested in larger animal models, e.g. pigs, which
better resemble human conditions (Ylä-Herttuala et al., 2004). From an ethical point
of view, all vascular gene therapy trials are based on local transfection of somatic
cells. However, when more powerful vectors are developed, undesired risks, such as
possible integration of the vector leading to pathological effects of the original virus,
may increase and need to be carefully monitored. Overall, vascular gene therapy is
proceeding rapidly mainly due to its increasingly important role in the management
of various diseases and the easy access to target cells. In addition, in most vascular
diseases, only transient expression of the transgene is required in order to reach a
therapeutic goal. As with any therapy, further studies and clinical trials will ensure
both the safety and the efficacy of vascular gene therapy. The present study attempts
to briefly summarize the basic gene transfer vectors, mouse model of atherosclerosis,
and vascular endothelial growth factors, which are nowadays widely used in vascular
gene therapy studies.
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gene therapy studies.
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2. REVIEW OF THE LITERATURE
2.1. Pathogenesis of atherosclerosis
Atherosclerosis is a common cause of mortality especially in the western countries.
Major risk factors are hypercholesterolemia due to high serum levels of LDL and low
levels of HDL and diabetes, smoking, male gender, low physical activity and genetic
heritance. The pathogenesis of atherosclerosis starts as early as in childhood in a
response to injury or dysfunction of the endothelium caused by shear stress,
inflammation and oxidized lipoproteins. Progression of atherosclerosis can be
classified as three steps: early lesions containing foam cells or fatty streaks,
intermediate lesions to atheroma and finally advanced/more complicated lesions with
possible plaque rupture.  (Ylä-Herttuala et al., 1986; Kannel and Larson, 1993; Stary
et al., 1995 and 2000; Ross, 1999).
Figure 1. Lesion types I-VI
Type I lesion = eccentric intimal thickening (increased number of macrophages, small groups of
foam cells)
 Type II lesion = increased accumulation of intracellular lipids in macrophages and SMCs (foam
cells in layers)
Type III lesion = accumulation of extracellular lipids in small separate pools between SMCs ,
Type IV lesion = large disruptive extracellular lipid core (atheroma)
Type V lesion = thickening of the superficial intima that overlies the lipid core, formation of a
fibrous cap (SMC collagen)
 Type VI lesion = a lesion complicated by a surface defect (rupture, erosion, calcified nodule) and
thrombosis.
Type IV Type V Type VI
Type I Type II Type III
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Figure 2. Development of the lesions
1A. Development of type I and type II lesions
Hypercholesterolemia leads to LDL accumulation and oxidation in the arterial intima.LDL
oxidation induces VCAM-1 in endothelial cells and more monocytes and T-cells enter through the
vascular wall. Their migration through the endothelial layer is stimulated by chemokines such as
MCP-1, which is expressed both in macrophages and smooth muscle cells. Both VCAM-1 and
MCP-1 expressions are considered as important steps of early lesion formation. This accumulation
of macrophages and T-cells and modified lipid droplets/lipoproteins leads through type I to type II
lesions, so called fatty streaks with normal intima structure.(Nelken et al., 1991; Stary et la.,
1995;Liyama et al., 1999; Hansson, 2001)
1B. Development of type III and type IV lesions
 More cytokines and intracellular mechanisms are activated: activation of T-cells leads to
production of interferon (IFNg), which activates macrophages and regulates smooth muscle and
endothelial functions. PDGFs stimulate smooth muscle cell proliferation
and migration from media to the growing lesion. Activated macrophages produce proinflammatory
cytokines such as tumor necrosis factor (TNFa) and IL-1, which can induce adhesive properties on
endothelial cells (EC)and make matrix metalloproteinases (MMP).In addition, both T-cells and
macrophages produce cytotoxic factors, which contribute to apoptosis. At this stage, lesions (type
III to IV) have typical fibrious cap and score with extracellular lipids, cholesterol crystals and
calcium. (Lindner and Reidy, 1995; Stary et al.,1994 and 1995; Hansson, 2001)
Development of type V and type VI lesions
Step one and two are still active, especially on the shoulder areas of complicated lesions. The
lesion is composed of a smooth muscle cell cap with fibrotic cells and extracellular matrix and
under the cap lies a fibrotic plaque with necrotic core and free cholesterol. These lesions can further
be classified as stable or vulnerable plaques. Stable plaque consists of a thick fibrous cap with a
small lipid core. In contrast, vulnerable plaque has a large lipid core, a thin cap and often shoulder
regions consisting of active macrophages and T-cells with intraplaque angiogenesis, which are
modified from
Hansson,
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typical areas for plaque rupture. In addition, the stable plaque may transform into the vulderable one.
(Stary et al., 1994 and 1995; Hansson, 2001, Lindstedt and  Kovanen, 2004)
2.2 Mouse as a model of atherosclerosis
2.2.1. History
Thirty years ago, all atherosclerotic studies with mice were done in normal mice or
mice with spontaneous mutations (Thompson 1969). Mice are highly resistant to
atherosclerosis as compared with humans. The main reasons are, firstly, that the
mouse liver can secrete both apoB-48 and apoB-100-containing lipoproteins and
therefore only 30% of liver VLDL can be converted to LDL and, secondly, mice do
not express cholesteryl ester transfer protein (CETP, which transfers cholesterol
esters from HDL to VLDL and triglycerides in the opposite direction in humans).
There are also some minor differences in hepatic lipase activity and higher affinity of
ApoE to its receptors (Petersson et al., 1986; Agellon et al., 1991; Greeve et al.,
1993). Because of these factors, wild type mice have high HDL and low LDL
concentrations and do not develop atherosclerosis in normal conditions.
Because dietary fat is one of the most important environmental factors associated
with cardiovascular diseases, the first models were based on high-fat diets and strains
susceptible to atherosclerosis. The first atherogenic diet contained 39% fat, 5%
cholesterol and 2% cholic acid. As this diet was quite toxic, it was soon modified in
the laboratory of Paigen by lowering the total concentrations to 15% fat, 1.25%
cholesterol and 0.5% cholic acid, and is now referred to as the high-fat or Paigen diet
(Nishina et al., 1990). Even if this diet has been lately criticized for the toxic
metabolic effects of cholate, it is still widely used. Later on more physiological diets
were developed, e.g. the Western type diet consisting of 21% fat by weight, 0.15%
cholesterol and no cholic acid (Plump et al., 1992; Machleder et al., 1997; Lichtman
et al., 1999). The most susceptible strains such as C57BL/6 developed atherosclerosis.
However, the lesions were very small foam cells (fatty streaks) and were present only
in the aortic valve leaflets. The C57BL/6 mice have recently gained popularity as
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controls in the analysis of atherosclerosis and today most of the atherosclerotic mouse
models have this atherogenic C57BL/6 background (Paigen et al., 1985 and 1990).
For many years, the mouse was not expected to be the model of atherosclerosis,
because some of the mice did not survive on high-fat atherogenic diets, most of the
mouse strains did not develop lesions and the pathology of the lesions was different
from human atherosclerosis. In the early 1980s, Brinster et al. (1981) developed a
new technique to create transgenic mice involving direct microinjection of cloned
DNA into the pronuclei, where transgene is stably integrated into the mouse genome.
In addition, in the late 1980s, two groups reported the isolation of pluripotent
embryonic stem (ES) cells (Bradley et al., 1984; Greaves et al., 1985), which can be
genetically modified in vitro. At the same time, homologous recombination was
discovered (Smithies et al., 1985; Thomas and Capecchi 1987), and the first knockout
mouse was born. (Doetschman et al., 1987). These technologies changed the situation
dramatically by enabling generation of mice with targeted inactivation or over-
expression of the different genes. The first true mouse models of atherosclerosis were
created; apolipoprotein E (apoE)-deficient mice in 1992 (Piedrahita et al.; Plump et
al.) and LDL receptor (LDLR)-deficient mice in 1993 (Ishibashi et al.). Both mice
have contributed to new practical models and a better understanding of the
development and genetics of atherosclerosis in mice. Later, several other mouse
models have been developed (Breslow 1996; Plump 1997) and new technologies
created, including point mutations, the Cre/loxP system and inducible promoters,
which allow temporal and spatial control of the genes (Sauer and Henderson 1988;
Baron et al., 1999).
2.2.2 Mouse models of apoE
2.2.2.1 Apolipoprotein E
ApoE is a 34-kD glycoprotein, which is a structural component of chylomicrons,
VLDL, IDL and HDL. It is responsible for the clearance of remnant lipoproteins
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through the LDL receptor and the chylomicron remnant receptor by the liver (Mahley
and Huang, 1999). ApoE is synthesized mainly in the liver, brain, and other tissues,
but also in the vessel wall by macrophages. It consists of three major isoforms (apoE2,
apoE3 and apoE4) of which apoE3 is the most common. This polymorphism is
associated with the biological functions of apoE as well as cholesterol levels. ApoE4
allele is responsible for an increased risk of CHD and Alzheimer’s disease (Davignon
et al., 1988; Corder et al., 1993). Genetic deficiency of apoE2 in humans is associated
with defective binding to LDLR and type III hyperlipoproteinemia. This severe
hypercholesterolemia is due to accumulations of chylomicrons and VLDL remnant
lipoproteins leading to yellow lipid-laden xanthomas in the skin and atherosclerosis.
(Ghiselli et al., 1981).
2.2.2.2 Apolipoprotein E-deficient mice (apoE-/-)
Since its inception, the ApoE-/- mouse model has been the most widely used mouse
model of atherosclerosis (Piedrahita et al., 1992; Plump et al., 1992; Zhang et al.,
1992). The ApoE-/- mouse has total plasma cholesterol concentrations 4-5 times
higher and 45% lower HDL cholesterol than the C57BL/6 mouse. Feeding apoE-
deficient mice with Western type diet raises cholesterol concentrations to 25 mM,
mainly in VLDL particles, but also in LDL resulting in extreme hypercholesterolemia
and atherosclerosis. Lesions start with an initial fatty streak, which progresses to
complex lesions with a fibrous cap and later to calcification (Nakashima et al., 1994;
Reddick et al., 1994; King et al., 2006). Although this model is the most widely used,
absence of apoE is rare in humans, and the most common cause of type III
hyperlipoproteinemia is the presence of a receptor-binding defective form of apoE2
(Mahley and Rall, 1995). The lipoproteins of the apoE-deficient mice are unlike most
human lipoproteins and these remnants have an abnormal lipid composition with a
high ratio of sphingomyelin to lecithin (Jeong et al., 1998). In addition, the lack of
macrophages to produce apoE as an arterial defence mechanism can be problematic
(Ross, 1999)
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2.2.2.3 ApoE3-Leiden transgenic mice
Several other mutations of apoE are known that lead to dominant inheritance of type
III hyperlipidemia, including the apoE3-Leiden gene (Havekes et al., 1986). ApoE3-
Leiden transgenic mice express the human dysfunctional apoE variant and develop
hyperlipidemia and atherosclerosis on a high-fat diet. Plasma cholesterol levels in
apoE3-Leiden mice on normal chow are similar to those of the C57BL/6 mouse, but
increase up to 30 mM on a high-fat diet. On a high-fat diet, these animals develop
atherosclerotic lesions ranging from early fatty streaks in the thoracic and abdominal
aorta to advanced lesions in the aortic arch. (Van Vlijmen et al., 1994; Groot et al.,
1996; Lutgens et al., 1999) Even if this model is moderate and needs a Paigen (high-
fat) diet, its background resembles more the typical, receptor binding-defective
human type III hyperlipoproteinemia.
2.2.3 Mouse models of LDLR
2.2.3.1 LDL receptor
The LDL receptor is an 115kD transmembrane glycoprotein, which has the key role
in removing cholesterol-carrying lipoproteins from plasma circulation. LDLR binds
both ApoB and ApoE containing lipoproteins; LDL, VLDL, IDL and chylomicrons
by the liver. Interestingly, lipoproteins with multiple copies of apoE have even 20
times higher affinity to LDLR than LDL with only one copy of ApoB100 (Brown and
Goldstein, 1986; Mahley et al. 1988). Deficiency of LDLR in humans is known as
familial hypercholesterolemia (FH). It is the first fully characterized genetic disease
of lipid metabolism and, without treatment, homozygous LDLR-deficient patients die
in early childhood. (Hobbs et al 1989; Marks et al., 2003).
2.2.3.2 The LDL receptor-deficient mice (LDLR-/-)
The LDLR-/- mouse is one of the earliest gene-targeted strains developed for
atherosclerosis research. It closely resembles the condition of human FH. LDLR-/-
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mice have delayed clearance of VLDL, IDL, and LDL from the plasma resulting in
moderate hypercholesterolemia and atherosclerosis mainly due to increases in plasma
IDL and LDL. (Ishibashi et al.1993). They have total plasma cholesterol
concentrations 2 times higher than C57BL/6 mice on normal chow. LDLR-/- mice
develop only fatty streaks without the diet, but when fed a Western type diet,
cholesterol concentration raises to 25 mM. The lesions can progress beyond fatty-
streaks to complex lesions with a fibrous cap and calcification. Similar to untreated
FH in humans, these mice also exhibit xanthomas and lesions have been found at
typical sites in the aorta and in other vessels (Ishibashi et al., 1994, Jalkanen et al.,
2003). The LDLR-/- mouse model was the first with lipoprotein profiles resembling
those of humans. Although this model is less aggressive than apoE-/- mice, the better
lipoprotein profile and normal arterial apoE-based defence have made it a popular
background to newer models of atherosclerosis.
2.2.4 Mouse models of apoB
2.2.4.1 Apolipoprotein B
The full-length apoB (apoB100) contains 4536 amino acid residues and is a structural
component of the VLDL secreted by the liver as well as IDL and LDL (Young, 1990;
Chan, 1992). Owing to a post-transcriptional modification, the apoB protein also
exists in a truncated form designated as apoB48 (Powell et al., 1987; Teng et al.,
1993). APOBEC-1 is an enzyme that converts codon 2153, CAA, to a stop codon,
UAA, with the presence of an APOBEC-1 complementation factor (ACF), thus
producing a truncated form of apoB48, which is a structural component of
chylomicrons. In humans, APOBEC-1 is expressed only by the intestine, whereas in
mice, both the intestine and the liver can produce apoB48 (Glickman et al., 1986;
Higuchi et al., 1992; Greeve et al., 1993). These two main isoforms of ApoB are
differently responsible for lipoprotein clearance. As ApoB48 lacks the LDL receptor-
binding domain of ApoB100, it cannot bind directly to the LDL receptor (Boren et al.,
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1998). Therefore, lipoproteins containing apoB48 possess multiple copies of apoE,
which increases its affinity to the LDL receptor and the LDL receptor-related protein
10–fold (Mahley et al., 1995; Farese et al., 1996a; Veniant et al., 1998). As a result,
apoB48-containing particles are cleared from the plasma in only a few minutes,
whereas LDL particles containing a single copy of apoB100 can stay in the plasma
for even a few days (Innerarity and Mahley, 1978). Other truncated forms of apoB
(sizes ranging from apoB27.6 to apoB89) have been discovered in humans with
familial hypobetalipoproteinemia (Young, 1990; Linton et al., 1993a; Schonfeld,
1995).
2.2.4.2 Most commonly used mouse models of apoB
All most commonly used models are based on the same principle; to correct the
difference of ApoB metabolism between humans and mice. The first model of human
apoB100 transgenic mice had only an apoB100 minigene resulting in very low
expression of human apoB100 (Chiesa et al., 1993). Soon two laboratories
independently developed transgenic mice which expressed high levels of human
apoB100 by using the entire human apoB gene expressed only in the liver (Linton et
al., 1993b; Callow et al., 1994; Kim and Young, 1998). Because homozygous
elimination of the apoB gene results in embryonic lethality, the first viable apoB
knockout mice produced a truncated form of apoB70. Later, other truncated models
were also created such as apoB39 and apoB83 (Homanics et al., 1993; Farese et al.,
1995; Kim et al., 1998; Kim andYoung, 1998). Targeted disruption of APOBEC-1
cleared that problem and resulted in mice that produce only apoB100 from the liver
(Hirano et al., 1996) and finally, using targeted mutagenesis of the apoB gene,
models were developed which synthesize exclusively apoB48 or apoB100 (Farese et
al., 1996b). All these human apoB-100 transgenic mice, APOBEC-ko and apoB100
only (apoB48-ko) mouse models, share similar lipoprotein profiles, which resemble
human lipoprotein profiles, including a distinct LDL cholesterol peak. On a normal
chow diet, these mouse models have mild hypercholesterolemia and
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human lipoprotein profiles, including a distinct LDL cholesterol peak. On a normal
chow diet, these mouse models have mild hypercholesterolemia and
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hypertriglyceridemia and they do not develop spontaneous atherosclerosis. However,
in response to a high-fat diet these mice develop moderate hypercholesterolemia and
atherosclerosis (Purcell-Huynh et al., 1995).
2.2.5 Mostly used combined mouse models
2.2.5.1 Mouse models of apoB and LDLR
Human apoB100 transgenic, APOBEC-ko, and apoB100 only (apoB48-ko) mouse
models have been crossed with LDLR-ko mice. The human apoB transgene with
LDLR-ko background (LDLR-/-/TG(apoB+/+) was made by Sanan et al., 1998, the
LDLR -/- and APOBEC-1 -/- mice were made by Powell-Braxton et al., 1998 and
LDLR-/- and apoB100 only mice (also known as LDLR/apoB48-ko mice) by Veniant
et al., 2000. All these mice have markedly elevated cholesterol and apoB100 levels
and they develop extensive atherosclerosis on a chow diet, which can be elevated
with Western type diet. This severe hypercholesterolemia is almost entirely due to the
accumulation of cholesterol in the apoB100 containing LDL particles. Moreover, the
lipoprotein profiles are similar to that seen in homozygous FH and in humans in
general. After Western type diet, complex lesions with a fibrous cap and calcification
were found.
2.2.5.2 Mouse models of apoE and LDLR
ApoE(-/-) and LDLR(-/-) mice were bred in 1994 by Ishibashi et al. This model has
total plasma cholesterol concentrations 6 times higher than the C57BL/6 mice on
normal chow. Lipoprotein profiles combine profiles from the basic models (apoE-ko
and LDLR-ko) with both elevated VLDL and LDL fraction. Unfortunately, apoE-
based arterial defence is still missing as in apoE-ko mice. ApoE and LDLR mice
develop extensive atherosclerosis on a chow diet and, on Western type and high-fat
diet, represent the most aggressive model of extreme atherosclerosis so that even
plaque rupture has been noted in lesions after a long diet duration.
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2.2.6. Brief comparison of the most commonly used mouse models of
atherosclerosis
Figure 3. Examples of the macroscopic lesion areas after 10 weeks on Western .
Arterial tree was perfused with PBS, with buffered formalin (10%) and post fixed with 10%
formalin for 2-4h. Whole aorta from the arch to the bifurcation was dissected, opened longitudinally
and analyzed for the presence of en face macroscopic lesions.
LDLR-ko ApoE-ko LDLR/ApoB48-ko      LDLR/ApoE-ko
Table 1.Typical atherosclerosis development of the different mouse models after
10 weeks on Western type diet
total cholesterol levels  (mM)            22+/-5             22+/-4            27+/-8               28+/-9         3.8+/-0.4
total triglycerides levels  (mM)        1.4+/-0.2         1.4+/-0.4        1.2+/-0.2          1.5+/-0.6       0.9+/-0.6
en face lesions area%/total area       11+/-3             12+/-3            13+/-2               18+/-3        not found
Cross-sectional lesion area                15-30%           20-45%         25-45%            42-55%      not found
LDLR-ko ApoE-ko LDLR/ApoB48-ko LDLR/ApoE-ko C57B
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Figure 4. Examples of the cross-sectional lesion areas after 10 weeks on Western
Cross-sectional lesion areas were quantified as whole lesion areas surrounded by the vascular ring
from the aortic sinus level, which is recognized by the presence of 3 valve cups.
Figure 5. Examples of the lesion development of the mouse models
A.Early fatty streak in all mouse models (type II)
B. Atheroma lesion with extracellular lipid of LDLR-ko mice (type III)
C. Complex lesion with a fibrous cap and calsificated necrotic core of LDLR/apoB48-ko mice (type
IV-V)
D. Complex lesion with a fibrous cap and calsificated necrotic core and mayby started hematoma of
LDLR/apoE-ko mice (type V to started type VI)
LDLR-ko apoE-ko
LDLR/apoB48-ko LDLR/apoE-ko
A
C
B
D
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Figure 6. Typical lipoprotein profiles of the different mouse models after
10 weeks on Western type diet
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2.2.7. Conclusion of the mouse models
Although mouse models differ from each other with respect to the total cholesterol
values, lipoprotein profiles and lesion progression times, they all seem to develop
atherosclerosis with similar lesion composition and distribution as seen in human
atherosclerosis: mostly in the aortic arch and the aortic branch points. Depending on
the model, diet, age and diet duration, the lesion types have varied from type I to type
III in moderate models to type I to type V in more severe models, and maybe even to
type VI in the most aggressive model (LDLR/apoE-ko mice).
Studies of atherosclerosis in mice versus humans have some important limitations, as
the size of the aortic roof as well as the basic lipoprotein background are different
(Rosenfeld et al. 2002; Cullen et al., 2003). In addition, lesion development in mice
starts above the endothelium instead of in the thickening intima. Furthermore, no
clear plaque rupture has been observed. One potential reason for this is that the
diameter of the aorta is less than 1 mm and as the vessel diameter decreases, the
surface tension increases exponentially. Consequently, the surface tension in mouse
may be so high as to prevent plaque rupture altogether. Still, some type of plaque
rupture has been found in the brachiocephalic artery in old ApoE-ko mice as well as
in the aorta and coronary arteries in ApoE/LDLR-ko mice even though differentiation
between plaque erosion and complete rupture of the fibrous cap has proven difficult
(Rosenfeld et al., 2000; Calara et al., 2001).
Despite these limitations, mice are the most utilized animal model today due to the
ability to make different genetic manipulations and the development of microsurgery.
Mice are now used in studies concerned with angioplasty, stenting and bypass
surgery (Ali et al., 2007; Zou et al., 1998). Further, there are models of denudation
and myocardial hypertrophy as well as myocardial and peripheral ischemia (Lindner
et al., 1993; Geisterfer-Lowrance et al. 1996; Carmeliet et al., 1997; Pashmforoush et
al., 2001; Metzler et al., 2001). In addition, MRI, ultrasound, biomicroscopy,
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echocardiogram, SPECT and PET have been developed to better describe mouse
anatomy (Fayad et al., 1998; James et al., 1998; Laitinen et al. 2006).
2.3 Vascular endothelial growth factor (VEGF) gene family and its receptors
Five mammalian members, including VEGF-A, -B, -C, -D and PlGF, have been
identified. Comparison of the amino acid sequences was reported by Achen et al. in
1998 (VEGF-A165, VEGF-B167, VEGF-C, VEGF-D and PlGF-2). VEGF family
members are structurally homologous cystine knot growth factors with disulfide-
linked dimeric proteins. They bind to their basic promoters VEGFR-1, VEGFR-2,
and VEGFR-3 with high affinity and selectivity. Although all members are
structurally homologous due their different binding properties and diversity among
the several isoforms, each family member plays a different role in angiogenesis and
lymphangiogenesis.
2.3.1 VEGF-A
Vascular endothelial growth factor (VEGF) or vascular permeability factor was first
described in the conditioned media of several rodent and human tumor cell lines and
finally purified in human cells in 1989 (Dvorak et al., 1979; Senger et al., 1983;
Senger et al., 1986; Connolly et al., 1989). VEGF-A consists of eight exons and,
through alternative mRNA splicing in exons 6 and 7, at least six VEGF isoforms of
variable number of amino acids have been found. VEGF121, VEGF 145 are
diffusible proteins, while approximately half of the VEGF165 is diffusible and the
other half binds to heparin-containing proteoglycans in the extracellular matrix like
the longer forms of VEGF (183, 189, 206) (Ferrara et al., 2003). VEGF is expressed
by various tumor cells, activated macrophages, hepatocytes, smooth muscle cells,
keratinocytes, renal glomerular epithelium and mesangial cells, embryonic fibroblasts
and bronchial and choroid plexus epithelium (Ferrara et al., 1991; Breier et al., 1992;
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Brown et al., 1992a/b; Iijima et al., 1993; Monacci et al., 1993; Pertovaara et al.,
1994; Fava et al., 1994) The major forms of VEGFs are VEGF121, VEGF165 and
VEGF 189 secreted by most cell types, while VEGF145 and VEGF206 seem to be
only from the placental origin (Robinson and Stringer., 2001; Ferrara et al., 2003;
Tammela et al., 2005). The gene expression of VEGF is strongly upregulated in
hypoxic conditions via hypoxia inducible factor (HIF) regulated elements of the gene,
via cytokines including the platelet-derived growth factor, epidermal growth factor,
fibroblast growth factor and transforming growth factor-ß, and via angiotensin II and
interleukin-1 (Stavri et al. 1995;Williams et al., 1995; Pugh and Ratcliffe, 2003;
Ferrara, 2004).
VEGF binds with high-affinity both to receptors with tyrosine kinase domains;
VEGFR-1 and VEGFR-2, and to neuropilin-1 (nrp) and -2 (receptors involved in
neuronal development and immunology) (Ferrara et al., 2003). Studies on knockout
mice of VEGF and its receptors have revealed that VEGF plays a critical role in the
development and formation of blood vessel networks. Even by knockout of a single
VEGF-A allele mice were unable to survive (Fong et al., 1995; Shalaby et al.,1995;
Ferrara et al., 1996; Carmeliet et al.,1996; Gerber et al., 1999). In addition, mice
expressing only VEGF-A120 but no longer isoforms die within two weeks after birth
because of cardiac failure (Carmeliet et al., 1999). In transgenic mice with tissue-
specific VEGF-A, increased vascularization and vascular permeability have been
noted (Okamoto et al., 1997; Detmar et al., 1998; Zeng et al., 1998; Dor et al., 2002;
Vogel et al.,2004). VEGF-A is the most important member of the VEGF family and,
besides angiogenesis, it has been shown to play a role in tumor growth, wound
healing, age-related macular degeneration, rheumatoid arthritis, diabetic retinopathy
and atherosclerosis (Ferrara and Bunting, 1996; Carmeliet et al. 1997).
2.3.2 VEGF-B
Vascular endothelial growth factor B was first described in 1996. VEGF-B consists
of eight exons and, through alternative splicing, exon six is deleted creating two
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different isoforms, VEGF-B 167 and VEGF-B 186. Due to the distinct C-terminal
regions, both VEGF-B 167 and VEGF-B 186 have different properties; VEGF-B 186
is diffusible, whereas VEGF-B 167 binds to heparin-containing proteoglycans in the
extracellular matrix, similarly to the longer forms of VEGF-A. The VEGF-B167 is
the main isoform, which accounts for more than 80% of the total VEGF-B transcripts.
The conservative N-terminal region of VEGF-B has high homology to the
corresponding regions in VEGF-A and PlGF, which can explain its binding
properties to VEGFR-1 and to nrp-1 and heterodimer formation between these three
members (Grimmond et al., 1996; Paavonen et al., 1996; Olofsson et al., 1996a/b;
Aase et al., 1996; Carmeliet et al., 2001; Scotney et al., 2002). The promoter region
of VEGF-B contains some important differences compared to VEGF-A, since it lacks
the hypoxia-inducible factor-1 site. Even though to date the molecular mechanisms
behind the regulation of VEGF-B expression are poorly understood, it is known not
to respond to hypoxia or to other typical VEGF-A inducers. such as growth factors
(Enholm et al., 1997; Ristimaki et al., 1998). VEGF-B is expressed in low levels in
most tissues, but especially in the heart, skeletal muscles, pancreas and brown fat.
VEGF-B can heterodimerize with VEGF and its special function may be related to
high-cellular energy metabolism and development of the heart (Olofsson et al., 1996b;
Enholm et al., 1997; Salven et al., 1998; Olofsson et al., 1999). In contrast to VEGF-
A knockout mice, VEGF-B-deficient mice are viable, and PlGF and VEGF-B double-
knockout mice showed no significant vascular phenotype (Bellomo et al., 2000;
Carmeliet et al., 2001). However, at least in one genetic background VEGF-B-ko
mice had smaller hearts and impaired recovery after experimental myocardial
infarctions. While VEGF-B may also have a special role in angiogenic responses in
collagen-induced arthritis and lung protection, the angiogenic effect of VEGF-B is
known to be weaker than VEGF-A (Bellomo et al., 2000; Rafii et al., 2003; Rissanen
et al., 2003).
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2.3.3 VEGF-C
The second crucial member of the VEGF family in the embryonic development is
VEGF-C. It consists of seven exons. In contrast to alternative splicing as with VEGF-
A and B, VEGF-C is produced as a precursor protein and becomes proteolytically
activated to 2 major forms; 31/29 kD heterodimer protein and 21 kD homodimer
protein. This process is mediated by proteases; Plasmin, Furin, PC5, and PC7. In
adults, VEGF-C is mostly expressed in the lymph nodes, small intestine, placenta,
ovary and heart, but has also been detected in the brain, liver, thymus, skeletal muscle,
spleen, prostate, testis, and colon (Lee et al., 1996; Joukov et al., 1996 and 1997;
McColl et al., 2003; Siegfried et al., 2003). The gene expression of VEGF-C is
upregulated by proinflammatory cytokines probably due to NF-?B binding sites in its
promoter area, but also by prostaglandin E2-mediated activation of COX-2 (Chilov et
al., 1996; Ristimäki et al., 1998; Su et al., 2004).
The longer form of VEGF-C (31/29 kD heterodimer) binds specifically to VEGFR-3
receptor unlike the shorter form (21 kD homodimer), which binds with high affinity
to both VEGFR- 2 and VEGFR-3 and also to nrp-2 (Enholm et al., 2001; Klagsbrun
et al., 2002; Kärkkäinen et al., 2004). In vivo, VEGF-C can act on both vascular and
lymphatic vessels. It induces vascular permeability through the activation of VEGFR-
2 whereas the VEGF-C/VEGFR-3 signaling pathway is known to be important for
lymphangiogenesis (Joukov et al., 1998; Saaristo et al., 2002). Mice lacking both
VEGF-C alleles die due to the lack of lymphatic vessels, while VEGF-C +/- mice
survive despite the defects in the lymphatic vessels, indicating that the VEGF-C
protein concentration is critical for the development of the lymphatic vasculature
(Kärkkäinen et al., 2001 and 2004). In addition, studies with transgenic mice over-
expressing VEGF-C under keratinocyte or pancreas-specific promoters have
demonstrated that the role of VEGF-C is mainly played in lymphangiogenesis
(Jeltsch et al., 1997; Mandriota et al., 2001; Veikkola et al., 2001). Besides
lymphangiogenesis, VEGF-C has been shown to play a special role in tumor
31
2.3.3 VEGF-C
The second crucial member of the VEGF family in the embryonic development is
VEGF-C. It consists of seven exons. In contrast to alternative splicing as with VEGF-
A and B, VEGF-C is produced as a precursor protein and becomes proteolytically
activated to 2 major forms; 31/29 kD heterodimer protein and 21 kD homodimer
protein. This process is mediated by proteases; Plasmin, Furin, PC5, and PC7. In
adults, VEGF-C is mostly expressed in the lymph nodes, small intestine, placenta,
ovary and heart, but has also been detected in the brain, liver, thymus, skeletal muscle,
spleen, prostate, testis, and colon (Lee et al., 1996; Joukov et al., 1996 and 1997;
McColl et al., 2003; Siegfried et al., 2003). The gene expression of VEGF-C is
upregulated by proinflammatory cytokines probably due to NF-?B binding sites in its
promoter area, but also by prostaglandin E2-mediated activation of COX-2 (Chilov et
al., 1996; Ristimäki et al., 1998; Su et al., 2004).
The longer form of VEGF-C (31/29 kD heterodimer) binds specifically to VEGFR-3
receptor unlike the shorter form (21 kD homodimer), which binds with high affinity
to both VEGFR- 2 and VEGFR-3 and also to nrp-2 (Enholm et al., 2001; Klagsbrun
et al., 2002; Kärkkäinen et al., 2004). In vivo, VEGF-C can act on both vascular and
lymphatic vessels. It induces vascular permeability through the activation of VEGFR-
2 whereas the VEGF-C/VEGFR-3 signaling pathway is known to be important for
lymphangiogenesis (Joukov et al., 1998; Saaristo et al., 2002). Mice lacking both
VEGF-C alleles die due to the lack of lymphatic vessels, while VEGF-C +/- mice
survive despite the defects in the lymphatic vessels, indicating that the VEGF-C
protein concentration is critical for the development of the lymphatic vasculature
(Kärkkäinen et al., 2001 and 2004). In addition, studies with transgenic mice over-
expressing VEGF-C under keratinocyte or pancreas-specific promoters have
demonstrated that the role of VEGF-C is mainly played in lymphangiogenesis
(Jeltsch et al., 1997; Mandriota et al., 2001; Veikkola et al., 2001). Besides
lymphangiogenesis, VEGF-C has been shown to play a special role in tumor
32
metastasis and maybe also in rheumatoid arthritis (Paavonen et al., 2002; He et al.,
2004)
2.3.4 VEGF-D
VEGF-D is the latest of the basic members of the VEGF family. It consists of eight
exons and, being most closely related to VEGF-C, it suggests that VEGF-C and
VEGF-D represent a subfamily of the VEGFs. Like VEGF-C, the human VEGF-D is
processed in its N-terminal and C-terminal ends, which are not found in other VEGF
family members. Full-length VEGF-D is secreted 53kD homodimer protein with a
central receptor-binding VEGF homology domain (VHD) and both C- and N-
terminal ends, and becomes proteolytically activated to 2 major isoforms; 30 kD
dimer (VHD and n-terminal) and, more importantly, 21 kD dimer protein (consists
only of VHD) (Yamada et al., 1997; Achen  et al. 1998; Stacker et al., 1999). VEGF-
D is present in most human tissues during embryogenesis, especially in the lung and
skin. In adults, VEGF-D is expressed in the heart, lung, skeletal muscle, colon and
small intestine, as well as in tumors (Achen et al. 1998; Farnebo et al., 1999;
Kurebayashi et al., 1999; Ruohola et al., 1999). The regulation of the VEGF-D gene
is still mostly unknown, but the expression is upregulated at least by NF-?B binding
sites like VEGF-C. Full-length VEGF-D binds to both VEGFR-2 and VEGFR-3, but
the mature short form of VEGF-D (21 kD dimer) has a much higher affinity to these
receptors (290 times greater to VEGFR-2 and 40 times to VEGFR-3). Owing to the
difference in binding affinity to its receptors, the mature short form of VEGF-D is
primarily angiogenic, whereas the full-length form is lymphangiogenic (Stacker et al.,
1999, Rissanen et al. 2003).
In contrast to VEGF-C knockout mice, VEGF-D-deficient mice are viable. This may
be due to the nonexistent role of VEGF-D during embryogenesis, but the difference
between human and mice VEGF-D may also play some role (mouse VEGF-D binds
only to VEGFR-3) (Baldwin et al., 2001 and 2005). However, VEGF-D may induce
lymphatic/angiogenic vessel growth in adults. Also, like VEGF-C, VEGF-D seems to
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have a role in tumor angiogenesis and lymphangiogenesis as well as lymphatic
metastasis. Furthermore, the mature form (21 kD) has as high an angiogenic effect as
VEGF-A (Achen  et al. 2001; Stacker et al., 2001; Ishii et al., 2004; He et al., 2004).
2.3.5 Other VEGFs
Placental growth factor (PIGF) was first identified in the placenta, and then also in
the heart and the lungs. PlGF is encoded by seven exons and has three human
isoforms; PlGF-1, -2 and -3 (Persico et al., 1999). PlGF homodimers bind to VEGFR-
1 and Nrp-1, while PlGF heterodimerization with VEGF may bind VEGFR-2 and
VEGFR-1/VEGFR-2 heterodimers in vitro. PIGF-deficient mice are viable without
any significant vascular phenotype, but skin-specific transgenic mice are associated
with increased inflammatory response and permeability (Carmeliet et al., 2001;
Odorisio et al., 2002; Nagy et al., 2003; Oura et al., 2003). PlGF-2 over-expression
after gene transfer has been associated with increased VEGF-A165 and VEGF-A121
levels, and induction of significant angiogenesis with a special role in the formation
of mature, leakage-resistant vessels. In general, PlGF expression is upregulated
during lung carcinoma and wound healing, and a possible role in atherosclerosis has
been described (Roy et al., 2005; Khurana et al., 2005).
VEGF-E was identified from parapoxvirus (Orf virus) and VEGF-F from snake
venoms. They both share similarities with VEGF-A, bind to VEGFR-2 and are able
to stimulate vascular permeability. Gene expression of VEGF-E induces a strong
angiogenic response in VEGF-E transgenic mice with minor side effects, such as
inflammation, as compared with VEGF-A. Moreover, peptides from VEGF-F have
been shown to block VEGF-A activity (Wise et al., 1999; Shibuya, 2003; Suto et al.,
2005; Yamazaki et al., 2005).
2.3.6 VEGFR-1
Vascular endothelial growth factor receptor-1 (VEGFR-1, also known as Flt-1) was
originally discovered from the human placental cDNA library. It is expressed in two
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forms via alternate splicing; a full-length, membrane-bound receptor VEGFR-1 and a
truncated, soluble receptor sVEGFR-1. Full-length VEGFR-1 is 180 kD glycoprotein
having seven extracellular immunoglobulin (Ig)-like domains, a single
transmembrane region and an intracellular tyrosine kinase domain with a kinase
insert sequence (Shibuya et al., 1990; Matthews et al., 1991; Pajusola et al., 1992).
The first three N-terminal Ig-like domains are responsible for ligand-binding and the
remaining four for receptor dimerization. The truncated sVEGFR-1 consists of only
the first six extracellular Ig-like domains (Kendall et al., 1996; Wiesmann et al., 1997;
Fuh et al., 1998). The expression of VEGFR-1 is primarily restricted to endothelial
cells, but it has also been noted in osteoblasts, monocytes/macrophages, pericytes,
placental tromboblasts, renal mesangial cells and in some haematopoietic stem cells.
VEGFR-1 can bind VEGF, VEGF-B and PlGF with high affinity. VEGFR-1
transmits only weak mitogenic signals, but the signaling properties of VEGFR-1 and
VEGFR-2 heterodimers are even higher than those of VEGFR-2 homodimer. In
contrast, the soluble form of VEGFR-1 can also form heterodimers with VEGFR-2,
thus blocking the signaling (Carmeliet et al., 2001; Huang et al., 2001; Zachary and
Gliki, 2001; Ferrara et al., 2003).
VEGFR-1 knockout mice die at E8.5 due to disorganization of blood vessels and
overgrowth of endothelial cells. However, mice lacking only the tyrosine kinase
domain of VEGFR-1 survive with near normal vasculature (Shalaby et al., 1995;
Fong et al., 1995; Hiratsuka et al., 1998). VEGFR-1 is associated with monocyte
chemotaxis and in that way to early steps of atherosclerosis. Additionally, VEGF and
PlGF-mediated migration of monocytes/macrophages and production of tissue factor
appear to be mediated by VEGFR-1 (Barleon et al., 1996; Clauss et al., 1996). High
levels of sVEGFR-1 occur in the plasma during pregnancy and in patients with
essential hypertension. While excess expression has been linked to pre-eclampsia,
significantly lower levels have been observed in the plasma of patients with
cardiovascular disease and in smokers (He et al., 1999; Belgore et al., 2001a/b;
Maynard et al., 2003). Both angiogenesis and hypoxia have been shown to upregulate
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VEGFR-1 expression, but even if PlGF has been shown to promote angiogenesis with
VEGFR-1, the main functions of VEGFR-1 are probably to limit VEGF/VEGFR-2-
mediated angiogenesis. VEGFR-1 can act as a decoy for VEGFR-2 due the lower
signaling properties and the soluble form can create inert receptors by dimerization
with VEGFR-2 or sequestering free ligand, mainly VEGF. In addition, in
experimental and clinical studies over-expression of sVEGFR-1 has been shown to
inhibit VEGF action and prevent neovasculogenesis and tumor growth (Goldman et
al., 1998; Takayama et al., 2001; Mori et al., 2001; Miotla et al., 2001; Autiero et al.,
2003).
2.3.7 VEGFR-2
VEGFR-2 (also known as KDR or Flk-1) is similar to VEGFR-1. It is expressed in
two forms via alternate splicing; a full-length, membrane-bound receptor VEGFR-2
and a soluble receptor sVEGFR-2. Full-length VEGFR-2 is an approximately 230 kD
glycoprotein having the same type of structure as VEGFR-1; 7 extracellular (Ig)-like
domains, transmembrane region and kinase insert domains in intracellular regions.
Like VEGFR-1, the dimerization and signaling is blocked in the same 4-7 Ig-like
parts of the extracellular domain (Tao et al., 2001; Terman et al., 2001). Like other
VEGFRs, VEGFR-2 is mainly expressed in endothelial cells, but also in neuronal
cells, osteoblasts, pancreatic duct cells, retinal progenitor cells, megakaryocytes and
haematopoietic stem cells. Compared to VEGFR-1, VEGFR-2 is more widely
distributed and expressed in all vessel-derived endothelial cells (Kaipainen et al.,
1993; Barleon et al., 1997; Ferrara et al., 2003).
VEGFR-2 bind VEGF-A, VEGF-C and VEGF-D (and also nonhuman VEGF-E and
F), but the isoforms are somewhat different. VEGF-A (isoforms 165, 186 and 206)
have high affinity and the 121 isoform needs nrp-1/2 to enhance the activity. In
VEGF-C, only the major/shorter form is efficiently bound to VEGFR-2, whereas in
VEGF-D, both isoforms can bind to the receptor, and the shorter form has the higher
affinity. In addition, PlGF is also able to bind to VEGFR-2, but only in the
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PlGF/VEGF-A heterodimer form and not in the homodimer form (Kendall et al.,
1994; Cao et al., 1996; Stacker, 1999; Kärkkäinen et al., 2004; Shraga-Heled et al.,
2007). The soluble forms of VEGFR-1 and VEGFR-2 are likewise different from
each another; sVEGFR-2 cannot compete with VEGF (binding is heparin dependent)
and can only partially inhibit cell migration, whereas soluble VEGFR-1 can almost
completely block VEGF-induced cell proliferation and migration (Roeckl et al.,
1998). Similar to VEGFR-1-deficient mice, VEGFR-2 knockout mice die at E9 due
to lack of development of the embryonic vasculature. VEGFR-2 is the most important
VEGF receptor in vascular endothelial cells and it plays an important role in
angiogenesis, vasodilatation, endothelial cell migration and proliferation (Shalaby et
al., 1995 and 1997; Wise et al., 1999; Zachary and Gliki, 2001).
2.3.8 VEGFR-3
VEGFR-3 (also known as Flk-4) is similar to VEGFR-1 and 2. It is expressed in two
forms via alternate splicing with minor differences to other receptors, the full-length
form having only six extracellular (Ig)-like domains. VEGFR-3 binds only VEGF-C
and VEGF-D and is upregulated in vascular and peripheral solid tumors. It is
expressed on all endothelia during development, but becomes later restricted to
lymphatic vessels (Pajusola et al., 1994; Kaipainen et al., 1995; Joukov et al., 1996;
Achen et al., 1998; Partanen t al., 1999; Skobe et al., 2001a/b; Hughes, 2001).
VEGFR-3 knockout mice die at E9.5 due to the lack of development of vasculature,
but the expression of VEGFR-3 becomes redundant as the vessels mature. In addition,
transgenic mice expressing soluble form of VEGFR-3 in the skin lacking dermal
lymphatic vessels suggest that VEGFR-3 in adults is crucial only in the process of
lymphangiogenesis. Mutations in VEGFR-3 have been linked to hereditary
lymphedema in humans and, besides lymphangiogenesis, VEGF-C/VEGFR-3
pathway has been shown to play a special role in tumor metastasis (Dumont et al.,
1998; Irrthum et al., 2000; Makinen et al., 2001; He et al., 2004).
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2.3.9 Neuropilins
The neuropilins (Nrp-1 and Nrp-2) have roles in immunology and neuronal
development, and they are also involved in angiogenesis by acting as co-receptors of
VEGFRs. Nrp-1 can bind VEGF, VEGF-B and PlGF affecting both VEGFR-1 and
VEGFR-2, whereas Npr-2 binds VEGF, VEGF-C and PlGF and may affect VEGFR-
3 pathway (Klagsbrun et al., 2002; Bagri and Tessier-Lavigne, 2002).  Nrp-1
expression is mostly found in endothelial arteries, whereas Nrp-2 is primarily
expressed in veins and lymphatic endothelium (Herzog et al., 2001). While Nrp-2
knockout mice have normal blood vasculature, Nrp-1-deficient mice die at E13 from
vascular defects like other VEGFRs-ko mice. Double knockout Nrp-1/Nrp-2 mice
have even higher phenotype resembling the VEGF and VEGFR-2 knockout mouse
models. In addition, over-expression of Nrp-1 leads to excessive formation of
capillaries and haemorrhages like over-expression of VEGF-A ( Nrp-1 regulates
VEGF-A165 levels). Mutated Nrp-2 mice have been associated with the formation of
small lymphatic vessels and capillaries (Kitsukawa et al., 1995; Kawasaki et al., 1999;
Yuan et al., 2002; Takashima et al., 2002).
2.3.10 Conclusion of VEGFs and VEGF receptors
The VEGF family members play important roles in arteriogenesis, angiogenesis and
lymphangiogenesis. Studies on knockout mice show that VEGF-A and its main
receptors VEGFR-1 and VEGFR-2 as well as Nrp-1 are critical in the development
and formation of blood vessel networks. VEGFR-3 is particularly crucial in the
development of total vasculature, whereas VEGF-C gene contributes only to the
development of lymphatic vessels. In contrast to others, the VEGF-B, PlGF, VEGF-D
and Nrp-2 deficient mice are viable without any significant vascular phenotype.
Angiogenesis and vascular permeability are mainly upregulated through VEGFR-2
homodimers and VEGFR-1/2 heterodimers, and partly also through VEGFR-1, and
efficiently down-regulated by soluble VEGFR-1 and its ability to form heterodimers
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with VEGFR-2. The most important ligands of angiogenic receptors are VEGF-A
(especially form 165), the short mature forms of VEGF-C and –D, and the
heterodimers of VEGF-A with VEGF-B or PlGF (PlGF/VEGF and VEGF-B/VEGF).
Lymphangiogenesis is upregulated mainly through VEGFR-3, especially by VEGF-C,
but also by VEGF-D.
Figure 7. VEGF gene family, their receptors and main signalling effect on the vascular wall.
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Lymphangiogenesis is upregulated mainly through VEGFR-3, especially by VEGF-C,
but also by VEGF-D.
Figure 7. VEGF gene family, their receptors and main signalling effect on the vascular wall.
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2.3.11 VEGF-A165 and Atherosclerosis
The role of VEGF-A in atherosclerosis is still controversial. In human arteries, it was
shown to be expressed mainly in SMC in normal arteries and the expression
increased from media to intima during atherogenesis (starting from fatty streaks). In
plaques and complicated lesions, VEGF-A was also detected in ECs and macrophage
rich areas and associated with plaque neovascularization (Inoue et al., 1998; Chen et
al., 1999; Rutanen et al., 2003; Belgore et al., 2004).
Although some animal studies, especially on ApoE-ko mice and rabbit model without
atherogenetic background, have suggested that VEGF can promote atherosclerosis
(Celletti et al., 2001; Khurana et al., 2004), in our study (III), using a more human-
like mouse model, no such effects were seen. Elevated endogenous serum levels of
VEGF have been shown during lipid oxidation and especially in some diseases like
diabetes (Lim et al., 2005; Trape et al., 2006). However, no clear correlation with
VEGF levels and the progression of atherosclerosis was found in clinical studies,
instead the protective role of VEGF has been indicated in several research articles
( Laitinen et al., 1997; Zachary et al., 2000; Chung et al, 2003; Porcu et al., 2004;
Howell et al., 2005; Susen et al., 2005).
In addition, it has been shown that vaccination against VEGFR-2 (the main VEGF-A
receptor) retards the progression of advanced lesions in the brachiocephalic artery in
ApoE-ko mice and in the aorta in LDLR-ko mice (Hauer et al., 2007; Petrovan et al.,
2007). In contrast, the expression of VEGFR-2 in human atherosclerotic arteries has
been shown to be even lower or similar than in normal arteries (Rutanen et al., 2003;
Belgore et al., 2004). VEGF can also destabilize coronary plaques by promoting
intralesion angiogenesis (Ramos et al., 1998; Dunmore et al., 2007). On the other
hand, Moreno et al. have suggested that microvessel formation may provide a
beneficial pathway for reverse lipid transport from the intima through the adventitia,
and that without these microvessels, lesions are more plaque-prone (Moreno et al.,
2004 and 2006). Indeed, recent clinical cancer trials using anti-VEGF-A antibodies
support the data that endogenous VEGF has an arterioprotective role in the human
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vasculature: blocking the VEGF activity with inhibitory antibodies increased the risk
of myocardial infarction and deep vein thrombosis (Ratner 2004).
Further studies are required, however, on the association between VEGF and
atherosclerosis. It is important to note that the VEGF gene is highly polymorphic,
affecting VEGF levels in different tissues, and that this polymorphism is connected to
a wide variety of diseases (Howell et al., 2005; Rogers and D’Amato, 2006).
Consequently, in order to establish the association between VEGF and atherosclerosis,
more human clinical data must be studied, where the disease types are carefully
classified and the levels of VEGF are investigated not only in the vasculature but also
in tissues.
2.4 Gene therapy vectors
2.4.1 Gene therapy in general
Gene therapy can be defined as the delivery of nucleic acids into the somatic cells in
order to achieve a beneficial effect. Shortly, it includes the transfer of full coding
genes or cDNAs to repair mutations or achieve over-expression of certain gene or to
block the expression/effect of the undesired gene by transferring short
oligonucleotides, siRNAs, miRNAs or decoy/antibody genes. Theoretically, the
major advantage of gene transfer is the ability to target the drug directly to specific
tissues with reduced systemic toxicity in contrast to classic pharmacology and only a
single administration can result in long-lasting (or short if desired) therapeutic effects.
Genetic engineering was first mentioned in the 1930s, but in general, the first
developments to be recognized were achieved during the 1950s and 1960s when the
first genes were transferred into bacterial and mammalian cells. In addition, in 1966,
the viruses were presented as the gene transfer vectors (Zinger and Lederberg, 1952;
Kay, 1961; Wolff and Lederberg, 1994, Gong et al., 2005). Gene transfer of “naked”
DNA is a highly inefficient process; only a small amount will pass into the cell where
it is rapidly broken down by cytoplasmic nucleases, and consequently it is now
exploited mainly in immunotherapeutic vaccination. In order to make the gene
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transfer more efficient, the nonviral and viral vectors were developed. In nonviral
gene therapy, liposomes are the most commonly used. They take advantage of the
cationic lipid bilayers that incorporate the nucleic acids and help cell entry. DNA
remains episomal, and the transfection efficiencies are still quite low except in certain
tissues like muscles, skin and tumors. To improve transfection efficiency liposomes
have been combined, for example, with the proteins of hemagglutinating virus, with
cationic polymers, and also hybrid layers have been used to make liposomes either
anionic or neutral. The main advantage of liposomes/polyplex systems is the total
lack of risk associated with viral vectors. In addition, they are easy and inexpensive to
produce, which has made the nonviral gene transfer one candidate for clinical use
(Dzau et al., 1996; Feldman and Steg 1997; Laitinen et al., 2000; Brown et al., 2001;
Stopeck et al, 2001; Liu, 2003).
2.4.2 Adenoviral vectors
Adenovirus is a double-stranded DNA virus, which was isolated already in 1953.
Today, at least 42 serotypes are known to infect humans, causing mild infection of the
upper respiratory tract, gastrointestinal tract, and the eye. The mostly used adenoviral
vector in gene therapy is based on serotype 5. It binds mainly to its specific receptor
called the coxsackievirus-adenovirus receptor (CAR), internalizes with the help of the
integrin receptors, and transports DNA into the cell nucleus, where it remains
episomal. Adenoviruses can efficiently infect both nondividing and dividing cells
(Rowe et al., 1953; Horwitz, 1990 and 2004; Wickham et al., 1993; Bergelson et al.,
1997; Tomko et al., 1997).
In the first-generation Ad5 vectors, the area of E1 region (replication genes) is
deleted and part of the areas of the E3 region is removed in order to increase the
capacity. The virus production needs helper cells (expressing E1A and E1B), like the
293 cell line, or the new PER C6 cell line, which has no overlapping E1 sequences
with the Ad5 vectors, eliminating the possibility of homologous recombination seen
in 293 cells (Graham et al., 1977; Bett et al., 1994; Fallaux et al., 1998). Due to the
41
transfer more efficient, the nonviral and viral vectors were developed. In nonviral
gene therapy, liposomes are the most commonly used. They take advantage of the
cationic lipid bilayers that incorporate the nucleic acids and help cell entry. DNA
remains episomal, and the transfection efficiencies are still quite low except in certain
tissues like muscles, skin and tumors. To improve transfection efficiency liposomes
have been combined, for example, with the proteins of hemagglutinating virus, with
cationic polymers, and also hybrid layers have been used to make liposomes either
anionic or neutral. The main advantage of liposomes/polyplex systems is the total
lack of risk associated with viral vectors. In addition, they are easy and inexpensive to
produce, which has made the nonviral gene transfer one candidate for clinical use
(Dzau et al., 1996; Feldman and Steg 1997; Laitinen et al., 2000; Brown et al., 2001;
Stopeck et al, 2001; Liu, 2003).
2.4.2 Adenoviral vectors
Adenovirus is a double-stranded DNA virus, which was isolated already in 1953.
Today, at least 42 serotypes are known to infect humans, causing mild infection of the
upper respiratory tract, gastrointestinal tract, and the eye. The mostly used adenoviral
vector in gene therapy is based on serotype 5. It binds mainly to its specific receptor
called the coxsackievirus-adenovirus receptor (CAR), internalizes with the help of the
integrin receptors, and transports DNA into the cell nucleus, where it remains
episomal. Adenoviruses can efficiently infect both nondividing and dividing cells
(Rowe et al., 1953; Horwitz, 1990 and 2004; Wickham et al., 1993; Bergelson et al.,
1997; Tomko et al., 1997).
In the first-generation Ad5 vectors, the area of E1 region (replication genes) is
deleted and part of the areas of the E3 region is removed in order to increase the
capacity. The virus production needs helper cells (expressing E1A and E1B), like the
293 cell line, or the new PER C6 cell line, which has no overlapping E1 sequences
with the Ad5 vectors, eliminating the possibility of homologous recombination seen
in 293 cells (Graham et al., 1977; Bett et al., 1994; Fallaux et al., 1998). Due to the
42
possibility of homologous recombination (regeneration of wild type viruses) and high
immune response in the first-generation viruses, the second-generation Ad vectors
with further deletions including areas of the E2A, E2B, and the E4 region were
designed (Wang et al., 1996; Amalfitano et al., 1998). It is noteworthy, however, that
the first- and second-generation adenoviruses have short transgene expression in vivo,
lasting only a few weeks. High-capacity or ”gutless” adenovirus vectors contain only
inverted terminal repeats and packaging signal . They are less easy to produce, as all
viral genes have to be in the helper virus with the packaging signal flanked by loxP
recognition sites. At present, the gutless vector can be produced as ”99% pure” and
production systems without a helper virus have been developed (Mitani et al., 1995;
Kochanek, 1999). The gutless Ad vectors will probably be the most used adenoviral
vectors in gene therapy in the future due their high transgene capacity (~ 37 kb),
lower immunogenity, and longer transgene expression time in vivo (Morsy et al.,
1998; Schiedner et al., 1998; Volpers and Kochanek, 2004).
The adenoviral vector is widely used in gene therapy. It has high transgene expression
and transfer efficiency because its special promoter CAR is expressed in most of the
cell types. However, this can also be problematic as, after systemic gene delivery,
adenovirus is mostly found in the liver. Moreover, after local delivery, small amounts
of adenoviruses can be found in nontargeted tissues. To overcome this problem,
inducible and cell-specific promoters have been used and viral capsid has been coated
using e.g. specific antibodies to permit more selective targeting (Kibbe et al., 2000;
Kaliberov et al., 2004; Greenberger et al., 2004; Song et al., 2005).
2.4.3 Adeno-associated viral vectors
The adeno-associated virus (AAV) is a single-stranded DNA virus, which requires
helper virus (adenovirus or herpesvirus) functions to replicate. The wild-type AAV
genome integrates in the host cell genome by site-specific recombination directed at
the short arm of chromosome 19 and maintains a latent state. The wild type AAV has
a 4.7 kb genome containing two open reading frames (ORFs) flanked by inverted
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terminal repeats (ITRs), and it is not associated with any known human disease
(Kotin et al., 1991; Weitzman et al., 1994; Jolly, 1994). There are at least 8 serotypes
of AAV with distinct tissue tropism. For example, AAV-5 has tropism for retina and
airway epithelial cells, AAV-6 for skeletal muscles, and AAV-8 for liver (Rabinowitz
et al., 2002; Blankinship et al., 2004; Davidoff et al., 2005; Nathwani et al., 2005).
AAV-2, and recently also AAV-5 are the most extensively studied serotypes. AAV-
2-based vectors use heparin sulphate proteoglycans (HSPG) as the primary receptor.
Also, the integrin receptor, the hepatocyte growth factor receptor c-Met, and the
fibroblast growth factor receptor 1 (FGFR1) have been proposed as coreceptors. In
contrast to AAV-2, AAV-5 serotype use platelet-derived growth factor receptors
(PDGFR–a? ?and -b) (Summerford and Samulski, 1998; Di Pasquale et al., 2003;
Kashiwakura et al., 2005).
In AAV-based vectors, most of the viral DNA has been deleted (only the ITRs are
left), leaving a transgene capacity of 4.9 kb. As a result, the AAV vectors have lost
the site-specific integration and vectors now integrate randomly and remain
predominantly episomal. As there is no host immune response against the AAV
vector-infected cells, this episomal DNA can also persist over months if not years in
nondividing cells (Miller et al., 2004). There are some practical issues to be
considered in the use of AAV in gene therapy. It is difficult to produce viral stocks in
high concentrations without low levels of contaminating helper virus, and the
maximal transgene area in the AAV has been found too small for many applications
(4.9 kb). Furthermore, when using larger inserts by splitting them over two vectors,
the efficiency was significantly reduced. In addition, many people seem to have
neutralizing antibodies against AAV, and after administration of the vector, a
humoral response was detected. This problem may be circumvented by using
different serotypes of AAV. Still, because AAV is not associated with human
diseases and allows effective long-term treatment, it is becoming a very attractive
vector for human gene therapy (Chirmule et al., 1999; Sun et al., 2000; Duan et al.,
2000).
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2.4.4 Retrovirus and lentivirus vectors
Retrovirus (usually murine leukemia virus; MuLV) is one of the original viral vectors
used in gene therapy. It is a linear single-stranded RNA virus, which can integrate
only into dividing cells. In contrast, lentiviruses are a subclass of retroviruses and
able to integrate into both dividing and nondividing cells with minimal immunogenity.
Both contain the same basic elements for cell entry, reverse transcription of the RNA
genome, and integration of the proviral DNA into the host cell chromosome.
Retro/lentivirus genome, as well as the envelope, can be easily manipulated and it can
hold larger transgenes compared to AAV. A so-called SIN vector, where the viral
promoter is replaced with tissue specific promoters has been used to generate
transcriptionally targeted viral vectors. In addition, the target cell selectivity has been
changed by the substitution of envelope. The mostly used envelope protein in viral
vectors is from the vesicular stomatitis virus (VSV-G), but other virus envelopes as
well as antibodies have been used as well. Unfortunately, retro- and lentiviruses can
be produced only with relatively low titers. In addition, their transfection efficiency is
low, and today the main use of these viruses in gene therapy trails is in ex-vivo
delivery (Cosset et al., 1985; Yu et al., 1986; Yee et al., 1987; Nabel et al., 1990;
Marin et al., 1996; De Palma et al., 2003; Kankkonen et al., 2004b). However, there
are also some safety concerns about contamination or possible mutation of these
recombinant viruses back to a pathogenic phenotype, the retroviral vectors being
derived from the leukemia virus and the lentiviral vectors from the human
immunodeficiency virus.  Indeed, leukemic transformation was noted in one clinical
trial, in which severe combined immunodeficiency disease was successfully treated
with bone marrow cells transduced with a therapeutic retroviral vector. In the future,
the lentiviruses, especially simian and feline immunodeficiency viruses, may be
preferred over retroviruses in gene therapy, because they are safer and can also infect
nondividing cells (Hacein-Bey-Abina et al., 2003; Kankkonen et al., 2004b).
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3.   AIMS OF THE STUDY
The aim of this thesis was to study different mouse models of atherosclerosis and
vascular endothelial growth factors, as VEGFs have important roles in vascular
gene therapy, with special attention to safety aspects.
In these studies, the specific goals were:
Article I; to characterize lesion development the in apoE3-Leiden mouse model.
Article II; to test potential usefulness of in situ PCR method in detecting viral DNA
from tissue samples
Article III; to evaluate the potential proatherogenic role of VEGFs by using systemic
gene transfer.
Article IV; to create a transgenic mouse model in order to evaluate long-term side
effects of VEGF-A gene therapy.
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4.   METHODS
Table 2.  Summarized methods used in studies (I-IV)
DNA and RNA PCR,RT-PCR II,III,IV
techniques in-situ PCR II
DNA cloning IV
DNA extraction I,II,IV
RNA extraction III
Subcloning IV
Sequensing II,IV
primer design II,IV
Used animals apoE-Leiden mice I
LDLR/ApoB48-ko mice III
VEGF-A transgenic mice IV
WHHL rabbits II
New Zealand White rabbits II
Used vectors AdVEGF-A,-B,-C,-D, rhVEGF-A III
AdCre IV
AdLacZ III
Retroviral LacZ II
Used diets High-fat diet I
Western type diet III
normal crow I, II,IV
Cholesterol diet for rabbits II
Plasma lipid analysis Cholesterol I,  III
Triglycerides I,  III
ASAT IV
CRP IV
Protein analysis Protein extraction III,IV
ELISA III, IV
Immunohistochemistry I,II,III,IV
In vivo analysis MRI IV
Lesion analysis en face and cross-sectional analysis I,III
Basic histological
stainings Masson tricrome IV
PAS IV
Alizar Red S IV
Movat staining III
X-gal staining II
Oil-red-O staining I
Statistical analysis Mean+/- SD I,III,IV
ANOVA III
Modified T-test III,IV
  Method
Study
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4.1 Generation and testing of the Cre controlled human VEGF-A165 expression
cassette and  creating the mouse model (IV)
First, an oligonucleotide containing restriction sites for Xho I and Sda I was cloned
into a Bgl II + Dra II –digested pcDNA3 vector (Invitrogen), and the CAG promoter
and rabbit  b-globin polyA were cloned into that. Secondly, a loxP site containing an
MCS oligolinker was cloned into the EcoRI site, and a blunted STOP-cassette was
incorporated into the Pml I site of the plasmid. The resulted plasmid was digested
with EcoRI and EcoRV and ligated with hVEGF-A165 cDNA, and the functionality
of the plasmid was tested in NIH-3T3 cells by Cre adenovirus at MOI 500.
Afterwards, the plasmid was digested with Sal I / Asc I and microinjected into the
CD2F1 hybrid mice (Balb/C x DBA2). Transgenic mice (pFloX-hVEGF-tg mice)
were analyzed from tail genomic DNA by PCR using specific primers for hVEGF-
A165 (5’-ccatgaactttctgctgtc-3’ and 5’-tcgtgagattctgccctc-3’) and an internal control
gene (ApoB with primers 5’-attgccttagatagtgcc-3’ and 5’-tttgctagatttacacgg-3’). F6
generation mice were used for the experiments.
4.2 Other experimental mouse models and diets (I, III)
In the article I, transgenic apoE3-Leiden mice (strain #2) were used for the
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provided ad libitum. All animal experiments were approved by the Experimental
Animal Committee of Kuopio University.
4.3 Gene transfers (III, IV)
Mice were injected via tail vein with recombinant E1-partial E3-deleted first
generation adenoviruses (1×109 pfu): Ad-VEGF-A, Ad-VEGF-B, Ad-VEGF-C, Ad-
VEGF-D (III) and Ad-Cre adenovirus (IV). In addition, rhVEGF-A protein (2 mg/kg)
and saline and Ad-LacZ were used (Laukkanen et al., 2000).
4.4 MRI (IV)
The anesthetized mice were positioned with straight-tighten hind limbs inside a
surface coil. MRI was performed at 9.4 T vertical Oxford magnet (Oxford
Instruments) interfaced to a SMIS console (Surrey Medical Imaging Systems) and fat
saturation was used. T2-weighted imaging was performed using a spin echo sequence
with two adiabatic refocusing pulses. Total echo time (TE) was 44 ms, repetition time
(TR) 2000 ms, resolution 256x128, field-of-view (FOV) 22x22 mm2 with 4 averages.
4.5 Plasma lipid analysis (I, III, IV)
Blood samples were taken 12-20 h after fasting depending of the diet, and plasma
lipid levels were measured using enzymatic kits; Cholesterol (Ecoline R 25, Merk
Diagnostica, or Boehringer Mannheim kit, cat. no 1442341) and triglycerides
(Ecoline R S+, Diagnostic Systems, or Boehringer Mannheim kit, cat. no 701882).
Routine clinical chemistry assays for aspartyl aminotransferase (ASAT) and C-
reactive protein (CRP) were done with EcolineR25 (Merck Diagnostica) and
Quickread CRP (Orion Diagnostica kits). Lipoprotein pattern in the article I was
analyzed using agarose gel electrophoresis (Beckman Lipoprotein electrophoresis, cat.
no 655910).
48
provided ad libitum. All animal experiments were approved by the Experimental
Animal Committee of Kuopio University.
4.3 Gene transfers (III, IV)
Mice were injected via tail vein with recombinant E1-partial E3-deleted first
generation adenoviruses (1×109 pfu): Ad-VEGF-A, Ad-VEGF-B, Ad-VEGF-C, Ad-
VEGF-D (III) and Ad-Cre adenovirus (IV). In addition, rhVEGF-A protein (2 mg/kg)
and saline and Ad-LacZ were used (Laukkanen et al., 2000).
4.4 MRI (IV)
The anesthetized mice were positioned with straight-tighten hind limbs inside a
surface coil. MRI was performed at 9.4 T vertical Oxford magnet (Oxford
Instruments) interfaced to a SMIS console (Surrey Medical Imaging Systems) and fat
saturation was used. T2-weighted imaging was performed using a spin echo sequence
with two adiabatic refocusing pulses. Total echo time (TE) was 44 ms, repetition time
(TR) 2000 ms, resolution 256x128, field-of-view (FOV) 22x22 mm2 with 4 averages.
4.5 Plasma lipid analysis (I, III, IV)
Blood samples were taken 12-20 h after fasting depending of the diet, and plasma
lipid levels were measured using enzymatic kits; Cholesterol (Ecoline R 25, Merk
Diagnostica, or Boehringer Mannheim kit, cat. no 1442341) and triglycerides
(Ecoline R S+, Diagnostic Systems, or Boehringer Mannheim kit, cat. no 701882).
Routine clinical chemistry assays for aspartyl aminotransferase (ASAT) and C-
reactive protein (CRP) were done with EcolineR25 (Merck Diagnostica) and
Quickread CRP (Orion Diagnostica kits). Lipoprotein pattern in the article I was
analyzed using agarose gel electrophoresis (Beckman Lipoprotein electrophoresis, cat.
no 655910).
49
4.6 RT-PCR (IV)
Total RNA was isolated with TRIzol compound (Invitrogen). RNA was DNAse
treated and digested before the cDNA synthesis in order to remove possible genomic
contamination. CDNA was synthesized from the total RNA with Superscript II
(Invitrogen) using random primers. Amplification of the transgene was performed
using inner primers for hVEGF-A165 as described by Bhardwaj et al. (2003).
4.7 Tissue samples (I-IV)
The animals were sacrificed with an overdose of Hypnorm/Dormicum mix (1:1) or
by using carbon dioxide. The right atrium was opened and blood was removed by
perfusion with PBS. Tissue samples were frozen in liquid nitrogen for RNA and
protein analyses, or perfusion-fixed (4% paraformaldehyde) for 10 min. The samples
were then postfixed for 2h, immersed overnight in 15% sucrose or PBS, and
embedded in paraffin or in OCT compound (I, III, IV). In the article II, liver samples
were obtained from WHHL rabbits 6-8 d after intraportal in vivo gene transfer, and
carotid artery samples from New Zealand White rabbits 7 d after implantation of ex
vivo gene transfected, autologous smooth muscle cells (SMC). Tissue samples were
fixed for 4 h and embedded in paraffin or OCT (Ylä-Herttuala et al., 1990; Pakkanen
et al., 1999; Turunen et al., 1999; Kankkonen et al., 2004b). Serial sections of these
tissues (6-8 µm) were used for immunohistochemical analysis, in situ PCR, and basic
staining.
4.8 Protein Extraction and ELISA (III, IV)
Proteins were extracted using T-PER Tissue Protein extraction reagent including
HaltTM protease inhibitors, and the total protein contents were assayed with BCATM
Protein Assay kit (Pierce, Rockford, IL, USA).
Possible cross-reaction between the mouse endogenous VEGF-A and human VEGF-
A was analyzed by activating a group of VEGF transgenic mice by AdCre or Ad
hVEGF-A165 in the distal right hind limb and in the calf of the left hind limb. Right
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hind limbs served as controls (IV). Levels in the different tissues after extraction and
in the circulating hVEGF-A, -B, -C and -D levels in sera were analyzed with ELISA
(III, IV) (R&D; Quantikine, mouse VEGF-A, human VEGF-A and VEGF-D, and
Zymed ELISA kit for VEGF-C). In addition, to test the effect of recombinant human
VEGF-B167, a sandwich ELISA was developed (III). Briefly, plates were coated
with 3 mg/ml of anti-human VEGF-B monoclonal antibody overnight at 4°C and
blocked by incubating with 3% BSA for 30 min at room temperature (RT). The
diluted plasma samples were then incubated overnight at 4°C, and affinity purified
rabbit anti-VEGF-B Ig was incubated for 2 h at RT (1 mg/ml in 1% BSA-PBS).
Bound rabbit Ig was detected by incubating the plates with alkaline phosphatase
conjugated anti-rabbit-IgG for 1.5 h at RT (1:3000 dilution in 1% BSA-PBS), and
visualized with NPP substrate. Between all steps, the plates were carefully washed
with PBST. Recombinant human VEGF-B167 protein was used as a standard.
4.9 Quantification of atherosclerotic lesions and active macrophage areas (I, III)
The arterial tree was briefly perfused with PBS and 10% formalin or 4% PFA and
postfixed for 2 to 6 h. The whole aorta, from the arch to the bifurcation, was dissected
and adventia was removed (in Study I oil-red-O stainings were used). The aortas
were opened longitudinally and analyzed for the presence of en face macroscopic
lesions using a MCID/M4-image analyzer (Imaging Research Inc., St. Catherine’s,
Ont., Canada). Cross-sectional lesion areas from the paraffin sections were quantified
as whole lesion areas surrounded by the vascular ring from the aortic sinus level,
which is recognized by the presence of 3 valve cups. Macrophage areas were
measured as the active region of the total lesion areas from the same sinus level
(analysis software from Media Cybernetics, Bethesda, MD, USA).
4.10 In situ PCR (II)
The paraffin sections were dewaxed in xylene, whereas the frozen sections were fixed
for 10 min in ice-cold acetone and air-dried. Slides were then heated 90 s at 105°C,
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transferred through graded alcohols and treated with proteinase K. Proteinase K was
inactivated and DNA was denaturated by boiling the slides in a microwave owen for
10 min in 0.1 M sitrate acid buffer. Slides were again dehydrated and dried. The
amplification mix (20 pmol of each primer, 0.2 mM dNTP, 0.3 mM BSA, 2.5 mM
MgCl2, 50 mM KCl, 10 mM Tris (pH 8.3), and 2U Dynazyme DNA polymerase)
was pipetted onto each slide, and a 20x40 mm coverslip was carefully sealed at the
edges with nail polish. PCR amplification was carried out using the following
conditions: denaturation step at 95°C for 8 min, followed by 40 cycles with 45 s at
95°C, 60 s at 58°C, 60 s at 72°C, and the final step at 72°C for 15 min.
To prevent diffusion of PCR products from the nucleus we used two set of primers:
upper primers from the retroviral LTR and the packaging signal (primer1; 5’–
caagaacagatgagacagc-3’ and primer2; 5’-ctgtccgattgtctagtgt-3’), and lower primers
from the LacZ gene (primer3; 5’ –ctcttcgctattacgcca-3’ and primer4; 5’-
tgaggggacgacgacagtat-3’). The lengths of the amplified products with the primers 1
and 4 and 2 and 3 were 650 bp and 500 bp, respectively. After amplification, the
slides were incubated in 100% ethanol for 5 min to remove the nail polish, followed
by washing in order to remove the amplification mix. Slides were then dehydrated
and air-dried. Detection was carried out using in situ hybridization with DIG-labeled
oligonucleotide sense-probe (5’-gctaactagctctgtatctggcggacccgtggtggaactgacgagttc-
3’), which recognizes the middle portion of the amplified fragment. (DIG
oligonucleotide tailing kit, Boehringer, Mannheim, Germany). Hybridization buffer
(50% deionized formamide, 10% dextran sulfate,1x Denhardt’s solution, 0.3 M NaCl,
10 mM Tris (pH 8), 0.1 mM EDTA pH 8.0, 0.1 mg/ml polyA) containing 10-20 pmol
/ml of DIG-labeled sense-probe was added and the slides were incubated at 95°C for
10 min in order to denaturate the amplified fragments, and then hybridized at 37°C
overnight. After hybridization, the sections were washed and the probe was detected
immunocytochemically using anti-DIG-alkaline phosphatase conjugate (dilution
1:600, final 1,25 U/ml) and NBT/BCIP color solution containing 2.0 mM levamisole.
The sections were counterstained with Eosin. The controls included sections where
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DNA polymerase or DIG-labeled sense-probe or anti-DIG-alkaline phosphatase were
omitted. In addition, irrelevant DIG-labeled oligoprobe and sections from
untransfected livers and carotid arteries were used.
4.11 Basic stainings (I-IV)
Sections were routinely stained with Hematoxylin-Eosin and, in selected cases, with
Masson Trichrom, PAS, and Alizarin Red S method for calcium in order to analyze
basic changes in the different tissues (IV). In addition, a modified Movat’s
pentachrome stain was used to analyze the cellular composition of the lesions (III),
X-gal staining to identify b-Gal-positive cells (4-16 h at 37°C) (II), and oil-red-O
staining to identify lipids (I) (Movat, 1955; Groot et al., 1996; Laitinen et al., 1997a).
Apoptosis after the gene transfer was evaluated by apoTaq kit (IV).
4.12 Immunohistochemistry (I-IV)
Basically, all samples were immunostained with an avidin-biotin-horseradish
peroxidase system (Vector Elite, Vector Labs) with few exceptions. Briefly, tissue
sections were treated with 0.3% hydrogen peroxide to inhibit endogenous peroxidase
activity. The primary antibodies were incubated for 1 h followed by the respective
biotinylated secondary antibodies and avidin-biotin complex, and the reaction was
visualized by using DAB or True Blue as a chromogen. Then, using mice tissues, the
sections were incubated overnight with 10% normal serum of the respective species
(III, IV) or with 4% serum cocktail (I). In the articles III and IV, the endogenous
avidin-biotin activity in the liver was further blocked by using an avidin/biotin
blocking kit (Vector Laboratories). Also, in the article IV, the cross-reaction was
surrounded with DAKO ARK kit (DakoCytomation) and low signaling effects were
amplified by tyramide signal amplification (TSA Biotin System, PerkinElmer). In all
articles, control immunostainings included incubations where primary antibodies
were omitted and incubations where primary antibodies were replaced with class- and
species-matched irrelevant immunoglobulins. Sections were counterstained with
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Eosin, Hematoxylin, or Mayer’s stain. All micrographs were taken using Olympus
AX-70 microscope and processed with Image-Pro PlusTM software (I, II) or
AnalySIS software (Soft Imaging System) (III, IV). In the article III,
neovascularization areas in the liver, aortic wall and adventitia were screened at low
magnification, and the most vascularized areas were analyzed in 5 different fields at
200x magnification at each section. In the article IV, the number of capillaries and
apoptosis in the liver section was counted in five randomly selected fields at 200x
magnification. The results were transformed to the number of capillaries per square
millimeter and the number of capillaries per section.
Table 3.  Antibodies used in immunohistochemistry
mMQ macrophages AIA31240
Accurate
Chemical 1:2000 - I,III
and Scientific 1:5000
LRP ?-chain  LRP
Moestrup et al.,
1990 1:25 II
LRP ?-chain Luoma et al., 1994 1:24 II
2F8 ScR-A Fraser et al., 1993 1:100 I
MAL-2 Oxidation -
Palinski et al.,
1990 1:1000 - I,III
spesific epitope 1:2000
HNE-7 Oxidation -
Palinski et al.,
1990 1:1000 I,III
spesific epitope
?-SMA smooth muscle  1A4 Sigma 1:20 - I,III
?-actin 1:200
 b-Gal bacterial b-Gal Sigma 1:200 II
CD-34 endothelium
HyCult
biotechnology BV 1:20 IV
PECAM-1 endothelium BD Pharmingen 1:20 - III,IV
1:50
LYVE-1 endothelium
Cursiefen et al.,
2002 1:1000 IV
pCNA
proliferating
cells Neomarkers 1:500 IV
hVEGF-A human VEGF-A R&D Systems 1:500 IV
Antibody Spesificity clone Producer dilution study
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4.13 Statistical Analysis (III, IV)
Calculations of the en face lesion areas, cross-sectional lesion areas, areas with
neovascularization and apoptosis were performed independently three times, and the
average values are reported. Data are expressed as mean ± SD and comparisons
between the groups were performed using ANOVA and modified T-test (SPSS 7.5,
SPSS Inc., Chicago, IL, USA). Value of P < 0.05 was considered statistically
significant.
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5. RESULTS AND DISCUSSION
The articles incorporating this thesis are presented separately due to the different
aspects of the individual studies. The main results and figures are presented and
briefly discussed for each article. The article II also includes a short introduction
presenting the basics of the methods used in that study.
5.1 Article I
Developed in 1993, the apoE3-Leiden transgenic mice are one the first mouse models
of atherosclerosis. It contains the human apoE3-Leiden variant and apo C1 genes,
which causes an inefficient plasma clearance of apoE-containing lipoprotein particles.
This model has been previously shown to develop atherosclerotic lesions in the aortic
root and in the thoracic and abdominal aorta on a high-fat (Paigen) diet. In addition,
the area covered by atherosclerotic lesions is proportional to cholesterol level in
VLDL and LDL-sized lipoprotein particles (Van der Maagdenberg et al., 1993; Van
Vlijmen et al., 1994 and 1996; Groot et al., 1996). The purpose of this study was to
examine the processes involved in lesion development and to see whether the
pathogenesis of atherosclerosis in this model has features similar to those in the
human disease. Total plasma cholesterol levels in the apoE3-Leiden mice on a regular
chow diet were on average 2.4 mmol/l and in the control C57BL/6J mice 1.8mmol/l.
Atherogenic diet led to an approximately 16-fold increase in the total plasma
cholesterol level (average 36 mmol/l) in the apoE3-Leiden mice, whereas only a 3-
fold increase was observed in the controls. In addition, the lipoprotein pattern in
apoE3-Leiden mice on atherogenic diet was characterized by an increase in the
VLDL and LDL fractions and a decrease in the HDL fraction as compared to the
control mice. After 4 months on atherogenic diet, the apoE3-Leiden mice developed
lesions ranging from early fatty streaks in the thoracic and abdominal aorta to
advanced lesions in the aortic arch. In the aortic arch, the percentage of lesions was
18%, whereas in the rest of the aorta, the percentage was 5%. In this study, we did
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This model has been previously shown to develop atherosclerotic lesions in the aortic
root and in the thoracic and abdominal aorta on a high-fat (Paigen) diet. In addition,
the area covered by atherosclerotic lesions is proportional to cholesterol level in
VLDL and LDL-sized lipoprotein particles (Van der Maagdenberg et al., 1993; Van
Vlijmen et al., 1994 and 1996; Groot et al., 1996). The purpose of this study was to
examine the processes involved in lesion development and to see whether the
pathogenesis of atherosclerosis in this model has features similar to those in the
human disease. Total plasma cholesterol levels in the apoE3-Leiden mice on a regular
chow diet were on average 2.4 mmol/l and in the control C57BL/6J mice 1.8mmol/l.
Atherogenic diet led to an approximately 16-fold increase in the total plasma
cholesterol level (average 36 mmol/l) in the apoE3-Leiden mice, whereas only a 3-
fold increase was observed in the controls. In addition, the lipoprotein pattern in
apoE3-Leiden mice on atherogenic diet was characterized by an increase in the
VLDL and LDL fractions and a decrease in the HDL fraction as compared to the
control mice. After 4 months on atherogenic diet, the apoE3-Leiden mice developed
lesions ranging from early fatty streaks in the thoracic and abdominal aorta to
advanced lesions in the aortic arch. In the aortic arch, the percentage of lesions was
18%, whereas in the rest of the aorta, the percentage was 5%. In this study, we did
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not find any measurable atherosclerosis in the control mice (C57BL/6J on
atherogenic diet).
Early lesions in the apoE3-Leiden mice typically consisted of lipid-filled
macrophage-derived foam cells. The internal elastic lamina was usually intact in the
early lesions and only some macrophages were detected in the media. Oxidation-
specific epitopes (malondialdehyde- and 4-hydroxynonenal-lysine adducts) and the
scavenger receptor-A were detected in the macrophage foam cells, whereas LRP was
mostly expressed in the smooth muscle cells. However, in some sections, LRP was
also present in macrophage-rich areas. In more advanced lesions; macrophages,
scavenger receptor, and oxidized epitopes were detected in shoulder regions and in
areas reminiscent of development of atheromatous core regions. In addition, LRP in
advanced lesions was mostly expressed in smooth muscle cells. Early signs of lesion
cap formation by smooth muscle cells, as well as thinning of the media and early core
formations were detected. The same pattern was seen in human lesions; scavenger
receptor and oxidation of lipoproteins have been previously shown to be expressed in
macrophages and LRP in both macrophages and smooth muscle cells in early and
advanced human lesions (Ylä-Herttuala et al., 1991 and 1996; Luoma et al., 1994).
Even if the atherosclerosis seen in apoE3-Leiden mice remained modest, the ability to
synthesize functional endogenous apoE is important. Since lesion macrophages
synthesize large quantities of apoE, local arterial production of mouse apoE may
attenuate atherogenesis. Several reports indicate that over-expression of apoE in
macrophages or in the arterial wall reduce atherosclerosis in transgenic mice. In
addition, bone marrow transplantation of apoE function in macrophages of apoE
knockout mice decreases atherosclerosis (Brown and Goldstein, 1983; Rosenfeld et
al., 1993; Bellosta et al., 1995; Shimano et al., 1995; Linton et al., 1995).
Consequently, the presence of endogenous mouse apoE synthesized in the liver,
macrophages and some other tissues makes apoE3-Leiden mice a useful model for
atherogenesis. Moreover, this model offers a possibility to study the effects of
56
not find any measurable atherosclerosis in the control mice (C57BL/6J on
atherogenic diet).
Early lesions in the apoE3-Leiden mice typically consisted of lipid-filled
macrophage-derived foam cells. The internal elastic lamina was usually intact in the
early lesions and only some macrophages were detected in the media. Oxidation-
specific epitopes (malondialdehyde- and 4-hydroxynonenal-lysine adducts) and the
scavenger receptor-A were detected in the macrophage foam cells, whereas LRP was
mostly expressed in the smooth muscle cells. However, in some sections, LRP was
also present in macrophage-rich areas. In more advanced lesions; macrophages,
scavenger receptor, and oxidized epitopes were detected in shoulder regions and in
areas reminiscent of development of atheromatous core regions. In addition, LRP in
advanced lesions was mostly expressed in smooth muscle cells. Early signs of lesion
cap formation by smooth muscle cells, as well as thinning of the media and early core
formations were detected. The same pattern was seen in human lesions; scavenger
receptor and oxidation of lipoproteins have been previously shown to be expressed in
macrophages and LRP in both macrophages and smooth muscle cells in early and
advanced human lesions (Ylä-Herttuala et al., 1991 and 1996; Luoma et al., 1994).
Even if the atherosclerosis seen in apoE3-Leiden mice remained modest, the ability to
synthesize functional endogenous apoE is important. Since lesion macrophages
synthesize large quantities of apoE, local arterial production of mouse apoE may
attenuate atherogenesis. Several reports indicate that over-expression of apoE in
macrophages or in the arterial wall reduce atherosclerosis in transgenic mice. In
addition, bone marrow transplantation of apoE function in macrophages of apoE
knockout mice decreases atherosclerosis (Brown and Goldstein, 1983; Rosenfeld et
al., 1993; Bellosta et al., 1995; Shimano et al., 1995; Linton et al., 1995).
Consequently, the presence of endogenous mouse apoE synthesized in the liver,
macrophages and some other tissues makes apoE3-Leiden mice a useful model for
atherogenesis. Moreover, this model offers a possibility to study the effects of
57
increased lipid levels without disturbing the macrophage functions and LDL
receptors.
Figure 8. Example of an advanced atherosclerotic lesion in aortic arch of apo E3-leiden
transgenic mice showing foam cells, smooth muscle cell cap formation and Immunostainings of
serial sections; (a) A low power field of the lesion (Macrophage staining). An arrow indicates the
area shown at higher power in (b)–(i); (b) part of the same section as in (a); (c) and (d) epitopes
characteristic of oxidized LDL (antiserums
 MAL-2 and HNE-7, respectively); (e) scavenger receptor, (f) control immunostaining,
(g) smooth muscle cell ?-actin, (h) LRP ?-chain, (i): LRP ?-chain
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Figure 9. Example of an early foam cell-rich atherosclerotic lesion of apo E3-leiden transgenic
mice.Immunostainings of serial sections; (a) Macrophages, (b) epitopes characteristic of oxidized
LDL, (c) scavenger receptor, (d)  LRP ?-chain,  (e)  LRP ?-chain, (f) control immunostaining
5.2 Article II
Gene transfer has been used for the treatment of several diseases. The transfer of
genes is achieved by utilizing a variety of vectors, including retroviruses,
adenoviruses, lentiviruses, adeno-associated viruses (AAV), and a number of non-
viral mechanisms. However, several safety concerns have also been raised, especially
with regard to stably integrated vectors. In situ PCR is a technique which combines
the high sensitivity of PCR with the advantages of in situ hybridization, i.e. exact
localization of the positive signal. It was first described in 1990 by Haase and his
colleagues and since then the method has been used to detect different viruses in
various tissues (Nuovo et al., 1991; Bates et al., 1997; Muciaccia et al., 1998; Walker
et al., 1998; Strappe et al., 1998).
In this study, in order to analyze relationships between gene expression and possible
morphological changes, we tested if in situ PCR technique can be used to localize
integrated viral vector DNA theoretically even a year after gene transfer. We selected
a retroviral vector (integrates to genome) with a lacZ reporter gene so that the
signaling localization from the in situ PCR can be compared to the actual transgene
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expression as measured by x-gal staining and b-galactosidase immunocytochemistry.
In order to ensure maximum enzyme activity, we used tissue samples 6-8 days after
the gene transfer.
First, the PCR protocol was optimized in tubes using the genomic DNA extracted
from the same paraffin or frozen sections. In addition, the specificity of the
amplification and the probe was confirmed by dot blot hybridization and sequencing.
The key step in the in situ PCR procedure was a controlled proteinase K pretreatment,
which permeabilizes the sections to permit entry of PCR reagents without leakage of
the PCR products or loss of morphology. Moreover, false positive signals may arise
from the misincorporation of labeled nucleotides if the direct in situ PCR detection
method was used (Long et al., 1993; Komminnoth and Werner et al., 1997). In order
to overcome these main problems we selected to use low proteinase K pretreatment
and quite a long amplification product (500-650 bp) without losing the effectiveness
of the PCR. Microwave irradiation was used to ease denaturation of double-stranded
DNA and to retrieve DNA from cross-linked material. For the final detection, a short
DIG-labeled oligonucleotide sense-probe was used (49bp), which recognizes the
middle portion of the amplified fragment but not the mRNAs from the transgene.
We found that in order to minimize diffusion of the PCR products, the smallest
proteinase K concentration producing a positive, sharp in situ PCR signal was the
best, and the short irradiation was essential. No differences were found in the
diffusion between the two tested 650 bp and 500 bp amplification products. When
very mild proteinase K pretreatment was used, the main problem was to deliver the
PCR reagents into the nucleus. To overcome this, the minimum of 35 cycles of PCR
amplification was needed for positive in situ PCR results. The increased background
signal was mainly due to endogenous AFOS-activity and excessive development time
after inefficient amplification, and could be lowered by using levamisole. After
successful amplification, the in situ PCR signal was bright and clearly visible, and the
background signal was negligible. We succeeded in obtaining reproducible positive
signals without any background for the paraffin and frozen tissue sections, and the
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signals localized in the same areas were positive for X-gal staining and for b-
galactosidase activity. Moreover, the reaction products did not diffuse out of the
positive area.
In this study, we developed an easy and efficient in situ PCR method, which can be
used to detect integrated transgene sequences in paraffin-embedded and frozen tissue
sections. The main improvements over previous techniques were that by using short
microwave irradiation and low proteinase K concentration no loss of morphology or
leaking of the PCR products were seen. Further, there was no need to use multiple
primer sets, post-PCR fixation of tissue sections, biotinylated primers or nucleotides
to prevent diffusion of PCR products. Furthermore, normal section slides could be
used. (Final selected conditions; pages 43-44, Methods 4.10; in situ PCR).
Figure 10. Comparison of the in situ PCR signals to B-galactosidase signals
Serial sections of frozen (A,D), paraffin-embedded (B,E) liver and paraffin-embedded (C,F) carotid
arteries.
(A-C) In situ PCR. Positive signals appear in blue-purple color (arrows). (D) X-gal staining for b-
galactosidase enzyme activity. Positive signals appear in blue (arrows). (E) b-Galactosidase
immunostaining. AEC was used as a substrate (red signal). Arrows point to the same cells as in B.
(F) b-Galactosidase immunostaining,signal reddish-brown (DAB as a substrate). Signal is localized
in the same area as the in situ PCR signal shown in C. Sections were counterstained with eosin or
hematoxylin.
A B C
D E F
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5.3 Article III
The role of vascular endothelial growth factors (VEGFs) in large arteries has been
proposed to be either vasculoprotective or proatherogenic. Because VEGF family
members are used for human therapy, it is important to know whether they could
enhance atherogenesis. On the basis of recent animal studies, concerns have been
raised about the potential proatherogenic effects of the VEGF gene or protein
therapies. Celletti et al. reported increased atherogenesis in apoE-deficient mice and
cholesterol-fed rabbits, and Moulton et al. showed that angiogenesis inhibitors can
reduce atherogenesis in apoE-deficient mice. During atherogenesis, expression of
VEGF-A in normal arteries increases. Still, the role of VEGF-A can be protective
through increasing the production of nitric oxide and prostacyclin, lowering LDL
toxicity, and mediating the antiapoptotic effects on endothelial cells. Conversely, the
capability of VEGF-A to stimulate monocyte/macrophage influx into the vessel wall
suggests that it may contribute to atherogenesis. In order to study the possible side-
effects of vascular gene therapy, we decided to test the effects of VEGF-A, -B, -C,
and -D on atherogenesis in LDL receptor (LDLR)/apoB48-deficient mice. Unlike in
apoE-knockout mice, in these mice the lipoprotein profile more closely resembles that
in humans. In addition, in this model, macrophages can normally produce and secrete
apoE. We also tested the effect of recombinant human (rh) VEGF-A protein to
compare this model with the previous results obtained in apoE-knockout mice
(Veniant et al.,1997; Laitinen et al., 1997b; Inoue et al., 1998; Ramos et al.,1998;
Moulton et al., 1999; Ferrara, 1999; Zachary et al., 2000; Kuzuya et al., 2001; Celletti
et al., 2001; Rutanen et al., 2003).
After tail-vein injections of adenoviruses, growth factors were detected by ELISA
assays. In systemic circulation, human VEGF-A, -B, -C, and -D were highly
expressed at 4 days after gene transfer and still detectable after 4 to 6 weeks. In
contrast to viral gene transfer, human VEGF-A protein was detectable only during a
few minutes and was already below the detection limit after 15 minutes. We also
evaluated the aortic expression of hVEGF-A transgene at 5 days after the systemic
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gene transfer and found that human VEGF-A was present in the aortas at 4 to 10
times higher concentrations than the mouse endogenous VEGF-A (451±290 pg/mg
hVEGF-A165, compared to 59±20 pg/mg mVEGF-A164). However, no statistically
significant differences were found between the study groups in serum total
cholesterol or triglyceride levels, en face atherosclerosis, or atherosclerotic lesion
areas measured from histological sections taken from the aortic sinus level. In
addition, no differences were found in the composition of the atherosclerotic lesions
either in the macrophage-derived foam cells or in the complicated lesions. Also, even
if there were more newly formed capillaries in the livers, especially in the VEGF-A
and -D–transduced groups, no increased neovascularization was found in the
atherosclerotic lesions or in the aortic adventitia. Our results showed that in this
mouse model, transient expression of VEGF growth factors, as verified by the
increased levels of the transduced proteins in peripheral blood and aortas, does not
enhance atherogenesis in large arteries. Thus, it is likely that at least some of the
results published earlier may be a result of the special properties of the apoE-
knockout mouse as a model for atherogenesis, because, in ApoE-ko mice, most of the
cholesterol is carried in chylomicron and VLDL particles and the lack of the ability
of macrophages to produce apoE protein has a significant impact on atherogenesis. It
is generally accepted that atherogenesis in apoE–/– mice is heavily dependent on
monocyte-macrophages and hence very susceptible to the potential effects of growth
factors on bone marrow. In contrast, in LDLR/apoB48-deficient mice, the majority of
cholesterol is transported in apoB100-containing lipoproteins (i.e. LDL fraction).
Also, in these mice, apoE production in macrophages is normal and the lesion
development is not as greatly affected by the inability of macrophages to secrete apoE.
Even though angiogenesis and atherogenesis share some common denominators, it is
important to recognize that atherogenesis is a different process from angiogenesis, and
that lipids, smooth muscle cell proliferation, and matrix accumulation play the major
roles in the development of atherosclerotic lesions.
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Figure 11. Effect of VEGF gene transfers on atherosclerosis of LDLR/apoB48-ko mice.
A, Total en face lesion areas of the aorta (%) after 12 weeks on diet. Aortas from the arch to the
bifurcation were opened longitudinally, pinned on a black surface, and analyzed for the presence of
macroscopic lesions. B and C, Cross-sectional lesion areas (%) after 12 weeks (B) and 22 weeks (C)
on diet. Areas were quantified by evaluation of the total lesion areas at the aortic sinus level, which
is recognized by 3 valve cusps. The results for individual mice are presented as scatterplots, and the
average of each group is indicated as a horizontal bar.
Figure 12. Representative examples of aortic lesion histology in transduced mice
(Movat pentachrome stainings)
All genes were transduced after 6 weeks on diet, and mice were sacrificed 6 weeks after the gene
transfers. Lesion composition in Ad-VEGF-A (A ), Ad-VEGF-B (B ), Ad-VEGF-C (C), Ad-VEGF-
D (D), AdLacZ (E), and saline control mice (F) was similar. Bar 100 mm.
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5.4 Article IV
The VEGF family has been shown to play a major role in vascular permeability,
angiogenesis, and lymphangiogenesis both during embryonic development and in
adults. VEGFs have also been used in clinical applications as recombinant proteins or
gene therapy. We generated a transgenic mouse model containing in its genome a
loxP-STOP inactivated hVEGF-A165 expression cassette, which can be activated by
Cre gene transfer in any tissue at any point during lifetime. The main reason for the
generation of the current transgenic model was to evaluate potential long-term side
effects of therapeutic hVEGF-A165 gene transfer. Unlike previous conventional
transgenic models, this model leads to the expression of hVEGF-A165 in only a low
number of cells in the target tissues in adult mice. In this article, the model was used
to study short and long-term effects of hVEGF-A165 over-expression on the pathology
of liver and various other tissues. Our study was based on previous research showing
that the systemic AdCre gene transfer primarily leads to the activation of hVEGF-
A165 in the liver, which is also the most common site of unintended biodistribution of
adenoviruses (Kilby et al., 1993; Hiltunen et al., 2000; Ylä-Herttuala and Martin,
2000; Ferrara et al., 2003; Ylä-Herttuala and  Alitalo, 2003).
Before creating the transgenic mice, the pFlox construct was tested in vitro and
AdCre and pFlox treated cells expressed hVEGF-A165 efficiently, reaching the peak
expression at 24 h after the transduction in contrast to cells transduced with pFlox
alone. In addition, MRI and ELISA verified the functionality of the hVEGF-A165
transgene in vivo. In MRI, typical angiogenic changes were seen after local AdCre
gene transfer as discrete edema. In ELISA, one week after the systemic gene transfer,
a wide range of hVEGF-A165 concentrations were detected in sera of the transgenic
mice in contrast to all control groups. Also, the possible cross-reactivity was tested
after local gene transfer, and no correlations were found between mouse endogenous
VEGF-A164 and hVEGF-A165 levels. During the next 3-4 weeks, serum hVEGF-A165
levels decreased, but low expression of hVEGF-A165 was present in many tissues
even after 18 months.  We estimate that only between 0.1% and 5% of all cells in the
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liver were transduced after the systemic AdCre gene transfer, and that the transgene
expression levels were only moderate in comparison to the previously generated
transgenic VEGF-A models. The adenoviral gene expression after systemic gene
transfer is typically seen in the liver, heart, kidneys, spleen, and lung. In addition, the
short-term effects were seen in the liver, heart, and spleen in most mice, but usually
not in the lungs or kidneys. This can be explained by comparison of the human and
mouse endogenous VEGF-A protein levels, since in the lungs, the hVEGF-A165
protein expression levels were only 2-8% of the mVEGF-A164 levels. Moreover, in
the kidneys, hVEGF-A165 protein expression rapidly decreased to undetectable levels.
At the early time points, 1-4 weeks after the AdCre gene transfer, histopathological
changes were found only in the livers, where an increased number of capillaries
featured active angiogenesis. In addition, the number of capillaries correlated with the
number of proliferating hepatocytes and the expression levels of hVEGF-A165.
Within 6 to 18 months after the AdCre gene transfer, increased vascularization and
proliferation of hepatocytes persisted in the livers, but morphological abnormalities
and signs of active angiogenesis were less common. All mice were surprisingly
healthy without any major consequences up to 13 months, except the typical
angiogenic changes mainly in the liver. Generally, all angiogenic changes were found
at the capillary level, as increased number and enlargement of vessels and local
angiogenic activity. In two mice, epicardial calcification was present in the heart,
which can be explained by hVEGF-A165 capacity to increase bone formation
(Hiltunen et al., 2003).
At the 18-month follow-up after the gene transfer, major consequences were seen;
one mouse developed a hepatocellular carcinoma in the liver and another had a
papillary adenocarcinoma in the lungs. We cannot exclude the possibility that
hVEGF-A165 played a role in the formation of tumors by inducing the growth of
dormant tumors, or by some other mechanism, especially in the case of hepatocellular
carcinoma, because only benign tumors were found in the control mice of the same
age. In addition, one hVEGF-A165 transgenic mouse died spontaneously 16 months
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after the gene transfer, showing abdominal cavity full of blood and many
macroscopical changes in different tissues, In the liver of this mouse hemangioma
was present. Furthermore, in the spleen, fibrous scars, local haemorrhage, and dilated
cystic spaces focally filled with blood resembling peliosis were found. In addition,
the whole paratubary area was highly vascularized with signs of old haemorrhage and
thrombus formation. All of these findings can be connected with local over-
expression of hVEGF-A165.
Figure 13. Major long-term histopathological changes after activation of hVEGF-A165
expression.
Typical changes in livers (A) and two malignant tumours (B,C) ;
A. Dilated hepatic vein branches and mild dilatation of the sinuses (marked with *),
(Haematoxylin-eosin).
 B.  Encapsulated hepatocellular carcinoma in the liver was highly necrotic and focally calcified
(Haematoxylineosin).
B. Papillary adenocarcinoma in lungs (Haematoxylineosin).
Bar: A,B,C 100mm
A
*
*
CB
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Figure 14. Examples of the hVEGF-A165 transgenic mouse, which died spontaneously 16
months after the gene transfer with abdominal cavity full of blood with many macroscopical
changes in different tissues.
*
*
D      G                          J
*
E                        H                   K
F                        I                          L
A                         B                                           C
B. Macroscopical changes in spleen, control spleen on the left. Microscopical sections in G-I;
fibrous scars formed by collagenous and elastic fibres surrounded by dilated cystic spaces,
focally filled with blood and revealing inconsistently CD34 positive lining.
G. HematoxylinEosin (an arrow points to an area shown in I)
H. CD34 immunostaining.
I. The same area as in G with higher magnification (stained with Masson Trichrom). Asterix in G and
H indicate the same area.Bar: I,J 500mm, K 100mm
A. Macroscopical changes in liver (box shows the area of the microscopical sections in D-F);
D. Cavernous hemangioma featuring focal hyalinization,
E. The same tumor mass area with higher magnification (haematoxylineosin)
F. Weak focal hVEGFA165 immunoreactivity was present in the same area (True Blue as a chromogen),
arrows indicate positive cells. Bar: F 500mm G,H 100mm
C. Macroscopical changes in paratubarian area (microscopical sections in J-L);
J. Cystically dilated paratubarian spaces with signs of old haemorrhage and thrombus formation
(marked with *), an open circle points to an area which was highly vascularized as shown in
K.(CD31 immunostaining) and a box indicates an area which revealed focal
hVEGFA165immunopositivity shown in L. (hVEGFA165 immunostaining).
Bar: L 1000mm, M,N 100mm
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6. SUMMARY AND CONCLUSIONS
In the article I, we tested our first atherosclerotic mouse model, apoE-Leiden. The
model was moderate and only early complicated lesions were found.  Still, in the
light of various postulated functions of apoE, the presence of endogenous mouse
apoE synthesized in the liver, macrophages and some other tissues makes apoE3-
Leiden mice a useful model for atherogenesis, because these animals offer a
possibility to study the effects of increased lipid levels without disturbing the
macrophage functions and LDL receptors. Furthermore, similarities in the
pathogenesis with the human disease suggest that apoE3-Leiden transgenic mice are
an attractive model for genetic, pathophysiological, and intervention studies of
cardiovascular diseases.
Articles II-IV are focused on safety studies related to gene therapy in general
and to VEGF-A in particular.
In the article II, the new method, in situ PCR, was tested. Today, gene transfer has
been used for the treatment of several diseases. However, several safety concerns
have been raised especially with regard to the stable integrated vectors. In situ PCR is
a technique which combines the high sensitivity of PCR with the advantages of in
situ hybridization, i.e. exact localization of the positive signal. In this study, we tested
if this method can be used to localize integrated viral vector DNA theoretically even
a year after the gene transfer. It was concluded that in situ PCR is a sensitive method
to localize integrated viral vector DNA in both paraffin and frozen sections of the
different tissues. Further, this precise histological localization of the signal is the
most important quality of the method allowing comparison between transgene
expression and morphology. Still, it is very important to recognize that controls must
always be included in every step of the method in order to avoid false positive signals.
68
6. SUMMARY AND CONCLUSIONS
In the article I, we tested our first atherosclerotic mouse model, apoE-Leiden. The
model was moderate and only early complicated lesions were found.  Still, in the
light of various postulated functions of apoE, the presence of endogenous mouse
apoE synthesized in the liver, macrophages and some other tissues makes apoE3-
Leiden mice a useful model for atherogenesis, because these animals offer a
possibility to study the effects of increased lipid levels without disturbing the
macrophage functions and LDL receptors. Furthermore, similarities in the
pathogenesis with the human disease suggest that apoE3-Leiden transgenic mice are
an attractive model for genetic, pathophysiological, and intervention studies of
cardiovascular diseases.
Articles II-IV are focused on safety studies related to gene therapy in general
and to VEGF-A in particular.
In the article II, the new method, in situ PCR, was tested. Today, gene transfer has
been used for the treatment of several diseases. However, several safety concerns
have been raised especially with regard to the stable integrated vectors. In situ PCR is
a technique which combines the high sensitivity of PCR with the advantages of in
situ hybridization, i.e. exact localization of the positive signal. In this study, we tested
if this method can be used to localize integrated viral vector DNA theoretically even
a year after the gene transfer. It was concluded that in situ PCR is a sensitive method
to localize integrated viral vector DNA in both paraffin and frozen sections of the
different tissues. Further, this precise histological localization of the signal is the
most important quality of the method allowing comparison between transgene
expression and morphology. Still, it is very important to recognize that controls must
always be included in every step of the method in order to avoid false positive signals.
69
In the article III, the short-term possible atherosgenic effect of VEGF family
members were studied in mouse model which most closely resembled the human
profiles and shared the same arterial defendence. The role of vascular endothelial
growth factors (VEGFs) in large arteries has been proposed to be either
vasculoprotective or proatherogenic. Because the VEGFs are used for human therapy,
it is important to know whether they might enhance atherogenesis. In conclusion, no
evidence of increased atherogenesis was found in LDLR/apoB48-deficient mice after
adenovirus-mediated systemic gene transfers of VEGF-A, -B, -C, and -D. The results
are in line with findings from recent phase II/III clinical trials and animal studies.
Even though most human trials have used local intracoronary or intramyocardial
delivery of VEGF genes or recombinant proteins, systemic delivery is the only
feasible nontraumatic approach for gene or recombinant protein delivery in mice.
However, we recognize that our results do not exclude the possibility of VEGF-
derived harmful effects potentially caused by higher doses or alternative delivery
routes. It is obvious that the possibility of enhanced atherogenesis should be carefully
monitored in forthcoming clinical trials involving VEGF recombinant proteins or
genes. The present results do not suggest any increased proatherogenic effects of the
members of the VEGF gene family when expressed transiently after systemic
adenoviral gene transfer.
In the article IV, a new mouse model was developed in order to study the potential
long-term side effects of therapeutic hVEGF-A165 gene transfer. The VEGF family
has been shown to play a major role in vascular permeability, angiogenesis, and
lymphangiogenesis both during embryonic development and in adults. VEGFs have
also been used in clinical applications as recombinant proteins or gene therapy. In
conclusion, we have created a transgenic mouse model which over-expresses
hVEGF-A165 after Cre-protein gene transfer. In this model, the levels of hVEGF-A165
expression were moderate and most mice were healthy without any major
consequences except typical angiogenic changes in the liver up to 18 months.
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However, one mouse died spontaneously because of bleeding into abdominal cavity
and having liver haemangioma, haemorrhagic paratubarian cystic lesions, and spleen
peliosis. More importantly, two mice developed malignant tumors (hepatocellular
carcinoma and lung adenocarcinoma), which were not seen in controls.  Thus, we
concluded that uncontrolled long-term expression of hVEGF-A165 may cause
significant pathological changes in target tissues, and tight regulation of the transgene
expression seems to be a prerequisite for all therapeutic applications aiming at long-
term expression of hVEGF-A165.
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